ELSEVIER

Journal of the Neurological Sciences 216 (2003) 193–205

Journal of the Neurological Sciences

www.elsevier.com/locate/jns

# Cumulative Author Index, Volumes 206–216 (2003)

Abbas Helmy, A., see Elwan, O. (211) 15
Abdel Shafy, S., see Elwan, O. (211) 15
Abdel-Naseer, M., see Elwan, O. (211) 15
Abe, H., see Kohshi, K. (209) 115
Abe, K., see Hanyu, H. (209) 25
Abe, K., see Ilieva, H. (215) 57
Ahsan Moosa, N.V., see Sylaja, P.N. (215) 9
Aiba, I., see Ito, Y. (209) 105
Aizawa, H., see Itoh, T. (214) 7
Akatsu, H., see Horimoto, Y. (216) 105
Akyüz, F., see Durmaz, R. (215) 87
Albers, D.S., see Lorenzl, S. (207) 71
Alcazar, A., see Cid, C. (206) 91
Alekseev, V.P., see Green, A.J.E. (212) 69
Aller, M.A., see Lopez, L. (212) 93
Alousi, S.S., see Petrov, T. (209) 31
Alvarez-Cermeño, J.C., see Cid, C. (206) 91
Alvord Jr, E.C., see Swanson, K.R. (216) 1
Ambrosio, S., see Barrachina, M. (215) 105
Anagnostouli, M., see Paraskevas, G.P. (215) 51
Ando, J., see Sakamaki, M. (209) 69
André, C., see de Freitas, G.R. (210) 31
Annunziata, P., Figura, N., Galli, R., Mugnaini, F. and Lenzi, C.
Association of anti-GM1 antibodies but not of anti-cytomegalovirus, *Campylobacter jejuni* and *Helicobacter pylori* IgG, with a poor outcome in Guillain–Barré syndrome (213) 55
Antonelli, G., see Bellomi, F. (215) 3
Antozzi, C., see Mantegazza, R. (212) 31
Aoki, Y., see Matsuyama, Z. (210) 91
Appel, S.H., see Trail, M. (209) 79
Appenzeller, O., Minko, T., Pozharov, V., Bonfichi, M., Malcovati, L., Gamboa, J. and Bernardi, L.
Gene expression in the Andes; relevance to neurology at sea level (207) 37
Arahata, Y., see Ito, Y. (209) 105
Araújo, Abelardo Q.-C., see Leite, A.C.C. (214) 49
Arai, H., see Ito, S. (216) 179
Arai, K., see Kato, N. (210) 57
Arakawa, K., Tomi, H., Tobimatsu, S. and Kira, J.-i.
Middle latency auditory-evoked potentials in myotonic dystrophy: relation to the size of the CTG trinucleotide repeat and intelligent quotient (207) 31
Araki, T., see Kato, H. (208) 9
Araya, S.-i., see Wang, H.-Y. (216) 61
Arenas, J., see Seijo-Martínez, M. (208) 87
Arias, J., see Lopez, L. (212) 93
Arias, J.L., see Lopez, L. (212) 93
Arima, M., see Santa, Y. (212) 79
Arimura, K., see Kiwaki, T. (206) 17
Arimura, K., see Umehara, F. (215) 111
Arimura, Y., see Kiwaki, T. (206) 17
Arimura, Y., see Umehara, F. (215) 111
Arpa, A., del Ser, T., Goda, G., Barba, R. and Bornstein, B.
Apolipoprotein E, angiotensin-converting enzyme and α-1-antichymotrypsin genotypes are not associated with post-stroke dementia (210) 77
Asano, A., see Inoue, N. (210) 105
Ashton-Prolla, P., see Gomes, I. (214) 21
Athanasas-Platsis, S., Zhang, B., Hillyard, N.C., Cavanagh, A.C., Csurhes, P.A., Morton, H. and McCombe, P.A.
Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis (214) 27
Au, W.L., Lim, T.C.C., Seow, D.C.C., Koh, P.L., Loh, N.K., Lim, M.S.F., Tan, I.K. and Yee, W.C.
Serial diffusion-weighted magnetic resonance imaging in adult-onset citrullinaemia (209) 101
Baggi, F., see Mantegazza, R. (212) 31
Baier, M., see Nguyen, L.T. (209) 93
Bakshi, R., see Bermel, R.A. (208) 57
Bakshi, R., see Horsfield, M.A. (216) 169
Balash, Y., see Schaafsma, J.D. (212) 47
Bamborschke, S.U., see Petereit, H.F. (206) 209
Bams, J.L., see Schaafsma, A. (210) 23
Bankl, H.C., see Rauschka, H. (208) 101
Barba, R., see Arpa, A. (210) 77
Barkhof, F., see Lycklama à Nijeholt, G. (206) 173
Barkhof, F., see Lazeron, R.H.C. (213) 29
Barnett, M.H., Williams, D.B., Day, S., Macaskill, P. and McLeod, J.G.
Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study (213) 1
Barrachina, M., Domínguez, I., Ambrosio, S., Secades, J., Lozano, R. and Ferrer, I.
Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells (215) 105
Barron, K.D.
Microglia: history, cytology, and reactions (207) 98
Bartels, A.L., see Schaafsma, J.D. (212) 47
Baumhackl, U., see Rauschka, H. (208) 101
Beal, M.F., see Lorenzl, S. (207) 71
Becker, J., see Gomes, I. (214) 21
Beggs, A.H., see Bönnemann, C.G. (206) 71
Beghi, E., see Mantegazza, R. (212) 31
Bellomi, F., Scagnolari, C., Tomassini, V., Gasperini, C., Paolillo, A., Pozzilli, C. and Antonelli, G.
Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years (215) 3
Bendersky, M., Rugilo, C., Kochen, S., Schuster, G. and Sica, R.E.P.
Magnetic resonance imaging identifies cytoarchitectonic subtypes of the normal human cerebral cortex (211) 75
Benedict, R.H.B., see Horsfield, M.A. (216) 169
Ben-Sasson, S.A., see Irony-Tur-Sinai, M. (206) 49
Bermel, R.A., Sharma, J., Tjoa, C.W., Puli, S.R. and Bakshi, R.
A semiautomated measure of whole-brain atrophy in multiple sclerosis (208) 57
Bernardi, L., see Appenzeller, O. (207) 37
Bernardi, M., see Zivadinov, R. (216) 113
Bernasconi, P., see Mantegazza, R. (212) 31

doi:10.1016/S0022-510X(03)00322-8

Bernasconi, S., see Rizzardini, M. (207) 51
Berry, I., see Clanet, M. (206) 139
Bersudsky, M., see Ifergane, G. (213) 11
Berzin, T., see Salloway, S. (206) 115
Bezerra, M., see de Freitas, G.R. (210) 31
Bianco, C., see Puccioni-Sohler, M. (207) 87
Bildirici, K., see Durmaz, R. (215) 87
Bill, P., see Bryer, A. (216) 47
Biller, J., see Mayer, T.O. (207) 5
Biousse, V., see Thambisetty, M. (208) 93
Birbeck, G.L. and Kalichi, E.M.N.
The functional status of people with epilepsy in rural sub-Saharan Africa (209) 65
Bjartmar, C., Wujek, J.R. and Trapp, B.D.
Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease (206) 165
Blesa, R., see Casademont, J. (206) 23
Bochynska, A., see Lojkowska, W. (216) 119
Bogousslavsky, J., see Kuntzer, T. (207) 77
Bonfichi, M., see Appenzeller, O. (207) 37
Bönnemann, C.G., Thompson, T.G., van der Ven, P.F.M., Goebel, H.H., Warlo, I., Vollmers, B., Reimann, J., Herms, J., Gautel, M., Takada, F., Beggs, A.H., Fürst, D.O., Kunkel, L.M., Hanefeld, F. and Schröder, R.
Filamin C accumulation is a strong but nonspecific immunohistochemical marker of core formation in muscle (206) 71
Booth, F.W., see Deschenes, M.R. (210) 5
Bornstein, B., see Arpa, A. (210) 77
Bozzao, A., see Tombini, M. (213) 83
Brannagan III, T.H. and Zhou, Y.
HIV-associated Guillain–Barré syndrome (208) 39
Bratina, A., see Zivadinov, R. (210) 73
Brenneis, C., see Kofler, M. (216) 67
Brenner, T., see Irony-Tur-Sinai, M. (206) 49
Bridge, C., see Swanson, K.R. (216) 1
Briones, M.L., see Servera, E. (209) 111
Brok, H.P.M., see 't Hart, B.A. (212) 21
Brown, C.M., Dütsch, M., Hecht, M.J., Neundörfer, B. and Hilz, M.J.
Assessment of cerebrovascular and cardiovascular responses to lower body negative pressure as a test of cerebral autoregulation (208) 71
Brown, C.M., see Hecht, M.J. (213) 47
Brownscheidle, C., see Nguyen, L.T. (209) 93
Brück, W., Kuhlmann, T. and Stadelmann, C.
Remyelination in multiple sclerosis (206) 181
Brune, N., see Hoffmann, V. (211) 81
Brusa, A., see Jones, S.J. (206) 193
Bryant, D., see Bryer, A. (216) 47
Bryer, A., Krause, A., Bill, P., Davids, V., Bryant, D., Butler, J., Heckmann, J., Ramesar, R. and Greenberg, J.
The hereditary adult-onset ataxias in South Africa (216) 47
Butler, J., see Bryer, A. (216) 47

Cacopardo, M., see Patti, F. (211) 55
Campos, Y., see Seijo-Martínez, M. (208) 87
Cantoni, L., see Rizzardini, M. (207) 51
Capone, J., see Govoni, V. (216) 99
Cardellach, F., see Casademont, J. (206) 23
Casademont, J., Miró, O., Rodriguez-Santiago, B., Viedma, P., Blesa, R. and and Cardellach, F.
Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease (206) 23
Casetta, I., see Govoni, V. (216) 99
Cassol, E., see Clanet, M. (206) 139
Castro del Río, M., see Seijo-Martínez, M. (208) 87
Castro del Río, M., see Seijo-Martínez, M. (209) 119
Cauraugh, J.H. and Kim, S.
Progress toward motor recovery with active neuromuscular stimulation: muscle activation pattern evidence after a stroke (207) 25
Cauraugh, J.H. and Kim, S.B.
Chronic stroke motor recovery: duration of active neuromuscular stimulation (215) 13
Cavanagh, A., see Harness, J. (216) 33
Cavanagh, A.C., see Zhang, B. (212) 37
Cavanagh, A.C., see Athanasas-Platsis, S. (214) 27
Cazzato, G., see Zivadinov, R. (210) 73
Cazzato, G., see Zivadinov, R. (216) 113
Cevoli, S., see Mochi, M. (213) 7
Chai, A., see Tan, E.-K. (216) 163
Chan, W.Y., see Chiu, T.W. (216) 143
Chandran, V.R., see Tan, E.-K. (216) 163
Chang, C.-Y., see Lin, J.-J. (209) 87
Chang, D.-C., see Lin, J.-J. (209) 87
Charlton, C.S., Ridding, M.C., Thompson, P.D. and Miles, T.S.
Prolonged peripheral nerve stimulation induces persistent changes in excitability of human motor cortex (208) 79
Cheema, S.S., see Pamphlett, R. (216) 95
Chen, M., Valenzuela, R.M. and Dhib-Jalbut, S.
Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor (215) 37
Cheng, Q., Wang, D.-S., Jiang, G.-X., Han, H., Zhang, Y., Wang, W.-Z. and Fredrikson, S.
Prospective study of clinical epidemiology of Guillain–Barré syndrome in Harbin, China (215) 63
Chimelli, L., see Puccioni-Sohler, M. (207) 87
Chin, R.L., Sherman, W.H., Sander, H.W., Hays, A.P. and Latov, N.
Etanercept (Enbrel®) therapy for chronic inflammatory demyelinating polyneuropathy (210) 19
Chinnery, P.F., Howel, D., Turnbull, D.M. and Johnson, M.A.
Clinical progression of mitochondrial myopathy is associated with the random accumulation of cytochrome *c* oxidase negative skeletal muscle fibres (211) 63
Chirichigno, J.W., see Lorenzl, S. (207) 71
Chishiki, T., see Sakamaki, M. (209) 69
Chiu, T.W., Poon, P.W.F., Chan, W.Y. and Yew, D.T.W.
Long-term changes of response in the inferior colliculus of senescence accelerated mice after early sound exposure (216) 143
Cho, K.H., see Lo, S.S. (214) 43
Chui, D.H., see Santa, Y. (212) 79
Chung, H., see Tan, E.-K. (216) 163
Chung, S.-W., see Kim, J.-S. (206) 31
Ciancio, M.R., see Patti, F. (211) 55
Cid, C., Alvarez-Cermeño, J.C., Regidor, I., Salinas, M. and Alcazar, A.
Low concentrations of glutamate induce apoptosis in cultured neurons: Implications for amyotrophic lateral sclerosis (206) 91
Cimadevilla, J.M., see Lopez, L. (212) 93
Claassen, J., Hirsch, L.J. and Mayer, S.A.
Treatment of status epilepticus: a survey of neurologists (211) 37
Clanet, M., Cassol, E., Manelfe, C. and Berry, I.
Clinical–MRI correlations in the secondary progressive phase of MS: lessons from the treatment trials (206) 139
Codella, M., see Holtmannspötter, M. (206) 27
Confalonieri, P., see Mantegazza, R. (212) 31
Confavreux, C., see Vukusic, S. (206) 135
Confavreux, C., see Vukusic, S. (206) 153
Connor, J.R.
Iron transport proteins in the diseased brain (207) 112
Cook, N.M., see Jacobs, D.A. (213) 77
Cornelio, F., see Mantegazza, R. (212) 31
Correia, S., see Salloway, S. (206) 115
Cortelli, P., see Mochi, M. (213) 7
Costello, F., see Kolb, S.J. (216) 11
Crosby, A.H., see Wilkinson, P.A. (216) 43

Csurhes, P.A., see Athanasas-Platsis, S. (214) 27
Cudkowicz, M.E., see Lorenzl, S. (207) 71
Curran, B.C., see Sakamaki, M. (209) 69

Danielsen, E.R., see Jeppesen, T.D. (214) 17
Danilova, A.P., see Green, A.J.E. (212) 69
Das, B.K., see Kalita, J. (208) 109
Davids, V., see Bryer, A. (216) 47
Day, S., see Barnett, M.H. (213) 1
De Carvalho, M., Turkman, A. and Swash, M.
Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis: the effect of upper and lower motor neuron lesion (210) 83
De Freitas, G.R., André, C., Bezerra, M., Nunes, R.G. and Vincent, M.
Persistence of isolated flow in the internal carotid artery in brain death (210) 31
De Jong, B.M., see Schaafsma, A. (210) 23
De Simone, R., see Tombini, M. (213) 83
De Sonneville, L., see Lazeron, R.H.C. (213) 29
Del Ser, T., see Arpa, A. (210) 77
Delisle, M.B., see Vidal, R. (207) 110
Dembinska-Kiec, A., see Slowik, A. (214) 11
Dennis, K., see Halpern, C. (208) 31
Deschenes, M.R., Will, K.M., Booth, F.W. and Gordon, S.E.
Unlike myofibers, neuromuscular junctions remain stable during prolonged muscle unloading (210) 5
Dewey Jr., R.B., see Frohman, E.M. (210) 65
Dharmasaroja, P.
Specificity of autoantibodies to epitopes of myelin proteins in multiple sclerosis (206) 7
Dhib-Jalbut, S., see Chen, M. (215) 37
DiMauro, S., see Mancuso, M. (209) 61
Doi, Y., see Morita, Y. (212) 7
Domínguez, I., see Barrachina, M. (215) 105
Doran, M., du Plessis, D.G., Enevoldson, T.P., Fletcher, N.A., Ghadiali, E. and Larner, A.J.
Pathological heterogeneity of clinically diagnosed corticobasal degeneration (216) 127
Dorcaratto, A., see Marini, V. (212) 75
Drulovic, J., see Markovic, M. (211) 67
Druschky, A., see Hilz, M.J. (216) 153
Druschky, K., see Hilz, M.J. (216) 153
Du Plessis, D.G., see Doran, M. (216) 127
Dujmovic, I., see Markovic, M. (211) 67
Dunand, M., see Kuntzer, T. (207) 77
Durmaz, R., Ertilav, K., Akyüz, F., Kanbak, G., Bildirici, K. and Tel, E.
Lazaroid U-74389G attenuates edema in rat brain subjected to post-ischemic reperfusion injury (215) 87
Dusenbery, K.E., see Lo, S.S. (214) 43
Dütsch, M., see Brown, C.M. (208) 71

Ehlers, J.A.C., see Gomes, I. (214) 21
El Faiuomy, N., see Elwan, O. (211) 15
Ellenbogen, J., see Kolb, S.J. (216) 11
Els, T., see Kassubek, J. (212) 85
Elwan, F., see Elwan, O. (211) 15
Elwan, O., Madkour, O., Elwan, F., Mostafa, M., Abbas Helmy, A., Abdel-Naseer, M., Abdel Shafy, S. and El Faiuomy, N.
Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study (211) 15
Endo, K., see Takashima, Y. (214) 37
Enevoldson, T.P., see Doran, M. (216) 127
Eriguchi, M., see Takashima, H. (207) 59
Erne, B., see Fluri, F. (207) 43
Ertilav, K., see Durmaz, R. (215) 87
Esiri, M.M., see Kennedy, P.G.E. (215) 27

Fallon, J., see Salloway, S. (206) 115
Fan, Y.H., see Mok, V.C.T. (216) 55
Fazekas, F., see Petereit, H.F. (206) 209
Felber, A., see Kofler, M. (216) 67
Feng, G., see Qin, W. (210) 35
Fernández Hojas, R., see Seijo-Martínez, M. (208) 87
Ferrò, M.T., see Mantegazza, R. (212) 31
Ferracin, F., see Fluri, F. (207) 43
Ferrer, I., see Barrachina, M. (215) 105
Ferrera, L., see Marini, V. (212) 75
Fidziańska, A. and Hausmanowa-Petrusewicz, I.
Architectural abnormalities in muscle nuclei. Ultrastructural differences between X-linked and autosomal dominant forms of EDMD (210) 47
Figura, N., see Annunziata, P. (213) 55
Filippi, M.
MRI–clinical correlations in the primary progressive course of MS: new insights into the disease pathophysiology from the application of magnetization transfer, diffusion tensor, and functional MRI (206) 157
Filippi, M., see Holtmannspötter, M. (206) 27
Filippi, M., see Horsfield, M.A. (216) 169
Filosto, M., see Mancuso, M. (209) 61
Fletcher, N.A., see Doran, M. (216) 127
Floris, R., see Tombini, M. (213) 83
Fluri, F., Ferracin, F., Erne, B. and Steck, A.J.
Microheterogeneity of anti-myelin-associated glycoprotein antibodies (207) 43
Fontoira, E., see Seijo-Martínez, M. (209) 119
Fontoira, M., see Seijo-Martínez, M. (209) 119
Fook-Chong, S.M.C., see Tan, E.-K. (216) 163
Forghani, B., see Morita, Y. (212) 7
Fredrikson, S., see Cheng, Q. (215) 63
Frohman, E.M., O'Suilleabhain, P., Dewey Jr. ,R.B., Frohman, T.C. and Kramer, P.D.
A new measure of dysconjugacy in INO: the first-pass amplitude (210) 65
Frohman, T.C., see Frohman, E.M. (210) 65
Frusho, K., see Yoshizawa, T. (215) 45
Fujimoto, S., see Hagiwara, N. (212) 99
Fujimoto, S., see Irie, F. (215) 115
Fukazawa, T., see Houzen, H. (211) 49
Fukuoka, T., see Umehara, F. (215) 111
Fukutake, T., see Ito, S. (206) 39
Fukutake, T., see Komatsu, K.-i. (216) 17
Fukutani, Y., see Kobayashi, K. (208) 17
Fung, K.-M., see Jacobs, D.A. (213) 77
Fürst, D.O., see Bönnemann, C.G. (206) 71
Furuya, H., see Osoegawa, M. (209) 5
Furuya, H., Yasuda, M., Terasawa, K.-j., Tanaka, K., Murai, H., Kira, J.-i. and Ohyagi, Y.
A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion (209) 75

Gajdusek, D.C., see Green, A.J.E. (212) 69
Galetta, S.L., see Kolb, S.J. (216) 11
Galli, R., see Annunziata, P. (213) 55
Gamboa, J., see Appenzeller, O. (207) 37
Garcia-Rill, E., see Uc, E.Y. (212) 1
Garrè, C., see Marini, V. (212) 75
Gasperini, C., see Bellomi, F. (215) 3
Gautel, M., see Bönnemann, C.G. (206) 71

Gerwig, M., Kastrup, O., Meyer, B.-U. and Niehaus, L.
Evaluation of cortical excitability by motor and phosphene thresholds in transcranial magnetic stimulation (215) 75
Ghadiali, E., see Doran, M. (216) 127
Ghetti, B., see Vidal, R. (207) 110
Giladi, N., see Schaafsma, J.D. (212) 47
Gilden, D.H., see Morita, Y. (212) 7
Giovannoni, G., see Rejdak, K. (208) 1
Giugliani, R., see Gomes, I. (214) 21
Glass, D., see Salloway, S. (206) 115
Goda, G., see Arpa, A. (210) 77
Goebel, H.H., see Bönnemann, C.G. (206) 71
Goldberg, H.I., see Jacobs, D.A. (213) 77
Goldfarb, L.G., see Green, A.J.E. (212) 69
Gomes, I., Nora, D.B., Becker, J., Ehlers, J.A.C., Schwartz, I.V.D., Giugliani, R., Ashton-Prolla, P. and Jardim, L.
Nerve conduction studies, electromyography and sympathetic skin response in Fabry's disease (214) 21
Gómez-Merino, E., see Servera, E. (209) 111
Gonçalves, R.R., see Puccioni-Sohler, M. (207) 87
Gonsette, R.E.
Mitoxantrone in progressive multiple sclerosis: when and how to treat? (206) 203
Gordon, S.E., see Deschenes, M.R. (210) 5
Goto, K., see Tagawa, K. (211) 23
Gourie-Devi, M. and Nalini, A.
Madras motor neuron disease variant, clinical features of seven patients (209) 13
Govoni, V., Granieri, E., Manconi, M., Capone, J. and Casetta, I.
Is there a decrease in Guillain–Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy (216) 99
Gran, B., see Li, J. (215) 95
Granieri, E., see Govoni, V. (216) 99
Green, A.J.E., Sivtseva, T.M., Danilova, A.P., Osakovsky, V.L., Vladimirtsev, V.A., Zeidler, M., Knight, R.S., Platonov, F.A., Shatunov, A., Alekseev, V.P., Krivoshapkin, V.G., Masters, C.L., Gajdusek, D.C. and Goldfarb, L.G.
Viliuisk encephalomyelitis: intrathecal synthesis of oligoclonal IgG (212) 69
Greenberg, J., see Bryer, A. (216) 47
Grinfeld, E., see Kennedy, P.G.E. (215) 27
Grossman, M., see Halpern, C. (208) 31
Gur, T., see Salloway, S. (206) 115
Gurevich, T., see Schaafsma, J.D. (212) 47

Haaxma-Reiche, H., see Schaafsma, A. (210) 23
Hagiwara, H., see Sakamaki, M. (209) 69
Hagiwara, N., Toyoda, K., Fujimoto, S. and Okada, Y.
Extensive bihemispheric ischemia caused by acute occlusion of three major arteries to the brain (212) 99
Hagiwara, N., see Irie, F. (215) 115
Hahn, A.F., see Kuntzer, T. (207) 77
Hall, W.A., see Lo, S.S. (214) 43
Halpern, C., McMillan, C., Moore, P., Dennis, K. and Grossman, M.
Calculation impairment in neurodegenerative diseases (208) 31
Hamaue, N., see Ogata, A. (206) 79
Hammen, , Stefan, H., Pauli, E., Schäfer, I., Huk, W. and Tomandl, B.
1H-MR spectroscopy: a promising method in distinguishing subgroups in temporal lobe epilepsy? (215) 21
Han, H., see Cheng, Q. (215) 63
Han, J., see Qin, W. (210) 35
Han, S.-R., see Kim, J.-S. (206) 31
Hanefeld, F., see Bönnemann, C.G. (206) 71
Hansen, K., see Jeppesen, T.D. (214) 17
Hanyu, H., Shimuzu, T., Tanaka, Y., Takasaki, M., Koizumi, K. and Abe, K.
Effect of age on regional cerebral blood flow patterns in Alzheimer's disease patients (209) 25
Harada, A., see Ochi, K. (208) 43
Harness, J., Cavanagh, A., Morton, H. and McCombe, P.
A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein (216) 33
Harris, Z.L.
Aceruloplasminemia (207) 108
Hart, P.E., see Wilkinson, P.A. (216) 43
Hartung, H.P., see Petereit, H.F. (206) 209
Hartwich, J., see Slowik, A. (214) 11
Hashimoto, K., see Itoh, T. (214) 7
Hattori, N., see Kobayashi, T. (207) 11
Hattori, T., see Ito, S. (206) 39
Hattori, T., see Ogawara, K. (210) 41
Hattori, T., see Kato, N. (210) 57
Hattori, T., see Komatsu, K.-i. (216) 17
Hattori, T., see Ito, S. (216) 179
Hausdorff, J.M., see Schaafsma, J.D. (212) 47
Hausmanowa-Petrusewicz, I., see Fidziańska, A. (210) 47
Hayasaka, K., see Numakura, C. (210) 61
Hayashi, M., see Kobayashi, K. (208) 17
Hayashi, M., see Matsuyama, Z. (210) 91
Hayashi, Y.K., see Tagawa, K. (211) 23
Hayflick, S.J.
Pantothenate kinase-associated neurodegeneration (formerly Hallervorden–Spatz Syndrome) (207) 106
Hays, A.P., see Chin, R.L. (210) 19
He, L., see Qin, W. (210) 35
Hecht, M.J., see Brown, C.M. (208) 71
Hecht, M.J., Brown, C.M., Mittelhamm, F., Werner, D., Heuss, D., Neundörfer, B. and Hilz, M.-J.
Increased hypoxic blood pressure response in patients with amyotrophic lateral sclerosis (213) 47
Heckmann, J., see Bryer, A. (216) 47
Hellwig, K., see Hoffmann, V. (211) 81
Herms, J., see Bönnemann, C.G. (206) 71
Herpers, M., see Kassubek, J. (212) 85
Heuss, D., see Hecht, M.J. (213) 47
Higaki, M., see Ochi, K. (208) 43
Hilgenberg, S.L., see Lorenzl, S. (207) 71
Hillyard, N.C., see Zhang, B. (212) 37
Hillyard, N.C., see Athanasas-Platsis, S. (214) 27
Hilz, M.J., see Brown, C.M. (208) 71
Hilz, M.-J., see Hecht, M.J. (213) 47
Hilz, M.J., Platsch, G., Druschky, K., Pauli, E., Kuwert, T., Stefan, H., Neundörfer, B. and Druschky, A.
Outcome of epilepsy surgery correlates with sympathetic modulation and neuroimaging of the heart (216) 153
Hirata, K., see Odaka, M. (210) 99
Hirata, K., see Odaka, M. (211) 93
Hirono, N., see Ishii, K. (215) 71
Hirsch, L.J., see Claassen, J. (211) 37
Hoffmann, V., Schimrigk, S., Islamova, S., Hellwig, K., Lukas, C., Brune, N., Pöhlau, D., Przuntek, H. and Müller, T.
Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients (211) 81
Holtmannspötter, M., Inglese, M., Rovaris, M., Rocca, M.A., Codella, M. and Filippi, M.
A diffusion tensor MRI study of basal ganglia from patients with ADEM (206) 27
Hommes, O.R., see Petereit, H.F. (206) 209

Horimoto, Y., Matsumoto, M., Nakazawa, H., Yuasa, H., Morishita, M., Akatsu, H., Ikari, H., Yamamoto, T. and Kosaka, K.
Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson's disease with dementia (216) 105
Horsfield, M.A., Rovaris, M., Rocca, M.A., Rossi, P., Benedict, R.H.B., Filippi, M. and Bakshi, R.
Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences (216) 169
Hou, J.-G. and Jankovic, J.
Movement disorders in Friedreich's ataxia (206) 59
Houzen, H., Niino, M., Kikuchi, S., Fukazawa, T., Nogoshi, S., Matsumoto, H. and Tashiro, K.
The prevalence and clinical characteristics of MS in northern Japan (211) 49
Hovanesian, V., see Salloway, S. (206) 115
Howel, D., see Chinnery, P.F. (211) 63
Hozumi, I., see Matsuyama, Z. (210) 91
Hughes, R.A.C.
Interferon beta 1a for secondary progressive multiple sclerosis (206) 199
Hui, A.C.F., see Mok, V.C.T. (216) 55
Huk, W., see Hammen, (215) 21
Hulette, C., see Salloway, S. (206) 115

Ibayashi, S., see Kishikawa, K. (213) 19
Ichikizaki, K., see Inamasu, J. (209) 55
Ifergane, G., Bersudsky, M., Kachko, L. and Wirguin, I.
Induction of conduction block by *Campylobacter jejuni* lipopolysaccharides and focal neural insult (213) 11
Igarashi, H., see Sakamaki, M. (209) 69
Iida, M., see Kishikawa, K. (213) 19
Ikari, H., see Horimoto, Y. (216) 105
Ikeda, J., see Ochi, K. (208) 43
Ikeda, Y., see Inoue, C. (215) 119
Ikeguchi, M., Touge, T., Nishiyama, Y., Takeuchi, H., Kuriyama, S. and Ohkawa, M.
Effects of successive repetitive transcranial magnetic stimulation on motor performances and brain perfusion in idiopathic Parkinson's disease (209) 41
Ilieva, H., Nagano, I., Murakami, T., Shiote, M., Shoji, M. and Abe, K.
Sustained induction of survival p-AKT and p-ERK signals after transient hypoxia in mice spinal cord with G93A mutant human SOD1 protein (215) 57
Imada, H., see Kohshi, K. (209) 115
Imai, Y., see Kato, H. (208) 9
Imamichi, Y., see Kobayashi, T. (207) 11
Inaba, S., see Ochi, H. (206) 109
Inamasu, J., Nakamura, Y. and Ichikizaki, K.
Induced hypothermia in experimental traumatic spinal cord injury: an update (209) 55
Inglese, M., see Holtmannspötter, M. (206) 27
Inoue, C., Ikeda, Y., Tanaka, M., Sakazume, Y. and Okamoto, K.
A case of mixed connective tissue disease showing a lymphoid follicle in muscle pathology (215) 119
Inoue, N., Kunishige, M., Yoshida, S., Oshima, Y., Ohnishi, Y., Kuroda, Y., Asano, A., Yoshino, H., Matsumoto, T. and Mitsui, T.
Dissociation between titer of anti-ganglioside antibody and severity of symptoms in a case of Guillain–Barré syndrome with treatment-related fluctuation (210) 105
Inoue, T., Takenoshita, M., Shibata, M., Nishimura, M., Sakaue, G., Shibata, S.C. and Mashimo, T.
Long-lasting effect of transcutaneous electrical nerve stimulation on the thermal hyperalgesia in the rat model of peripheral neuropathy (211) 43
Inoue, T., see Kishikawa, K. (213) 19
Inoue, T., see Irie, F. (215) 115
Inuzuka, T., see Matsuyama, Z. (210) 91
Irie, F., Fujimoto, S., Uda, K., Toyoda, K., Hagiwara, N., Inoue, T. and Okada, Y.
Primary intraventricular hemorrhage from dural arteriovenous fistula (215) 115
Irony-Tur-Sinai, M., Vlodavsky, I., Ben-Sasson, S.A., Pinto, F., Sicsic, C. and Brenner, T.
A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation (206) 49
Iseki, E., see Katsuse, O. (211) 29
Ishida, K., see Mitoma, H. (208) 51
Ishii, K., Mori, T., Hirono, N. and Mori, E.
Glucose metabolic dysfunction in subjects with a Clinical Dementia Rating of 0.5 (215) 71
Iskra, T., see Slowik, A. (214) 11
Islamova, S., see Hoffmann, V. (211) 81
Ito, E., see Ito, Y. (209) 105
Ito, K., see Ito, Y. (209) 105
Ito, S., Hattori, T., Fukutake, T. and Sugimoto, K.
Is atopic dermatitis a risk factor for intervertebral disc degeneration? A preliminary clinical and MRI study (206) 39
Ito, S., Kuwabara, S., Sakakibara, R., Oki, T., Arai, H., Oda, S. and Hattori, T.
Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis (216) 179
Ito, Y., Kato, T., Suzuki, T., Yokokawa, Y., Aiba, I., Arahata, Y., Ito, E., Ito, K., Yasuda, T. and Sobue, G.
Neuroradiologic and clinical abnormalities in dementia of diffuse neurofibrillary tangles with calcification (Kosaka–Shibayama disease) (209) 105
Itoh, K., see Kiwaki, T. (206) 17
Itoh, T., Aizawa, H., Hashimoto, K., Kimura, T., Katayama, T., Koyama, S., Yahara, O. and Kikuchi, K.
Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan (214) 7
Itoyama, Y., see Kato, H. (208) 9
Izumo, S., see Kiwaki, T. (206) 17
Izzi, F., see Tombini, M. (213) 83

Jacobs, D.A., Fung, K.-M., Cook, N.M., Schalepfer, W.W., Goldberg, H.I. and Stecker, M.M.
Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome (213) 77
Jacobs, L.D., see Nguyen, L.T. (209) 93
Jacobson, S., see Puccioni-Sohler, M. (207) 87
Jakubowska, T., see Lojkowska, W. (216) 119
Jankovic, J., see Hou, J.-G. (206) 59
Japp, G., see Petereit, H.F. (206) 209
Jardim, L., see Gomes, I. (214) 21
Jarosz, H., see Lojkowska, W. (216) 119
Jedrzejczak, T., see Lojkowska, W. (216) 119
Jeppesen, T.D., Schwartz, M., Hansen, K., Danielsen, E.R., Wibrand, F. and Vissing, J.
Late onset of stroke-like episode associated with a 3256C→T point mutation of mitochondrial DNA (214) 17
Jiang, G.-X., see Cheng, Q. (215) 63
Johkura, K., Joki, H., Johmura, Y., Momoo, T. and Kuroiwa, Y.
Combination of infarctions in the posterior inferior cerebellar artery and anterior spinal artery territories (207) 1
Johkura, K., see Susuki, K. (211) 89
Johmura, Y., see Johkura, K. (207) 1
Johnson, M.A., see Chinnery, P.F. (211) 63
Johnson, R., see Petrov, T. (209) 31

Joki, H., see Johkura, K. (207) 1
Jones, S.J. and Brusa, A.
Neurophysiological evidence for long-term repair of MS lesions: implications for axon protection (206) 193
Jongen, P.J.H., see Petereit, H.F. (206) 209
Juengling, F.D., see Kassubek, J. (212) 85

Kachko, L., see Ifergane, G. (213) 11
Kadoya, T., see Wada, M. (208) 67
Kaji, M., see Sato, Y. (212) 55
Kajimoto, Y., see Miwa, H. (211) 85
Kalichi, E.M.N., see Birbeck, G.L. (209) 65
Kalita, J., see Misra, U.K. (208) 25
Kalita, J., Ranjan, P., Misra, U.K. and Das, B.K.
Hemichorea: a rare presentation of tuberculoma (208) 109
Kamouchi, M., see Kishikawa, K. (213) 19
Kamoun, M., see Li, J. (215) 95
Kanai, M., see Numakura, C. (210) 61
Kanbak, G., see Durmaz, R. (215) 87
Kanno, M., Matsumoto, M., Togashi, H., Yoshioka, M. and Mano, Y.
Effects of repetitive transcranial magnetic stimulation on behavioral and neurochemical changes in rats during an elevated plus-maze test (211) 5
Kapaki, E., see Paraskevas, G.P. (215) 51
Karenberg, A., see Moog, F.P. (213) 15
Kasner, S.E., see Kolb, S.J. (216) 11
Kassubek, J., Juengling, F.D., Els, T., Spreer, J., Herpers, M., Krause, T., Moser, E. and Lücking, C.H.
Activation of a residual cortical network during painful stimulation in long-term postanoxic vegetative state: a $^{15}O-H_2O$ PET study (212) 85
Kastrup, O., see Gerwig, M. (215) 75
Katayama, T., see Itoh, T. (214) 7
Katayama, Y., see Sakamaki, M. (209) 69
Kato, H., Araki, T., Imai, Y., Takahashi, A. and Itoyama, Y.
Protection of dopaminergic neurons with a novel astrocyte modulating agent (*R*)-(−)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease (208) 9
Kato, N., Arai, K. and Hattori, T.
Study of the rostral midbrain atrophy in progressive supranuclear palsy (210) 57
Kato, T., see Wada, M. (208) 67
Kato, T., see Ito, Y. (209) 105
Katsuse, O., Iseki, E., Marui, W. and Kosaka, K.
Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies (211) 29
Kawabe, K., see Tagawa, K. (211) 23
Kawai, M., see Ogawa, M. (210) 53
Kawanami, T., see Wada, M. (208) 67
Kay, R., see Li, H. (207) 65
Keir, G., see Rejdak, K. (208) 1
Kennedy, P.G.E., Grinfeld, E. and Esiri, M.M.
Absence of detection of Varicella-Zoster virus DNA in temporal artery biopsies obtained from patients with giant cell arteritis (215) 27
Kertesz, A. and Munoz, D.G.
Primary progressive aphasia and Pick complex (206) 97
Kihira, T., see Miwa, H. (211) 85
Kihira, T., see Morita, S. (216) 183
Kijima, K., see Numakura, C. (210) 61
Kikuchi, K., see Itoh, T. (214) 7
Kikuchi, S., see Tamura, I. (209) 19
Kikuchi, S., see Houzen, H. (211) 49
Kim, B.-S., see Kim, J.-S. (206) 31
Kim, H.-J., see Kim, N.-H. (206) 65
Kim, J.-S., Han, S.-R., Chung, S.-W., Kim, B.-S., Lee, K.-S., Kim, Y.-I., Yang, D.-W., Kim, K.-S. and Kim, J.-W.
The apolipoprotein E ε4 haplotype is an important predictor for recurrence in ischemic cerebrovascular disease (206) 31
Kim, J.-W., see Kim, J.-S. (206) 31
Kim, K.-S., see Kim, J.-S. (206) 31
Kim, M., see Kim, N.-H. (206) 65
Kim, N.-H., Kim, H.-J., Kim, M. and Lee, K.-W.
A novel SOD1 gene mutation in a Korean family with amyotrophic lateral sclerosis (206) 65
Kim, S., see Cauraugh, J.H. (207) 25
Kim, S.B., see Cauraugh, J.H. (215) 13
Kim, Y.-I., see Kim, J.-S. (206) 31
Kimura, K., see Saito, K. (210) 95
Kimura, T., see Itoh, T. (214) 7
Kira, J.-i., see Ochi, H. (206) 109
Kira, J.-i., see Arakawa, K. (207) 31
Kira, J.-i., see Osoegawa, M. (209) 5
Kira, J.-i., see Furuya, H. (209) 75
Kirov, R., see Moyanova, S. (212) 59
Kishikawa, K., Kamouchi, M., Okada, Y., Inoue, T., Ibayashi, S. and Iida, M.
Effects of carotid endarterectomy on cerebral blood flow and neuropsychological test performance in patients with high-grade carotid stenosis (213) 19
Kitagawa, M., see Tamura, I. (209) 19
Kitaichi, M., see Mizuno, T. (213) 67
Kiwaki, T., Umehara, F., Arimura, Y., Izumo, S., Arimura, K., Itoh, K. and Osame, M.
The clinical and pathological features of peripheral neuropathy accompanied with HTLV-I associated myelopathy (206) 17
Knight, R.S., see Green, A.J.E. (212) 69
Kobayashi, K., Nakano, H., Hayashi, M., Shimazaki, M., Fukutani, Y., Sasaki, K., Sugimori, K. and Koshino, Y.
Association of phosphorylation site of tau protein with neuronal apoptosis in Alzheimer's disease (208) 17
Kobayashi, T., Matsumine, H., Zhang, J., Imamichi, Y., Mizuno, Y. and Hattori, N.
Pseudo-autosomal dominant inheritance of PARK2: two families with *parkin* gene mutations (207) 11
Koch, H.C., see Seyfert, S. (206) 85
Kochen, S., see Bendersky, M. (211) 75
Koeppen, A.H.
A brief history of brain iron research (207) 95
Kofler, M., Kronenberg, M.F., Brenneis, C., Felber, A. and Saltuari, L.
Cutaneous silent periods in intramedullary spinal cord lesions (216) 67
Koga, H., see Takashima, Y. (214) 37
Koga, M., see Ogawara, K. (210) 41
Koga, M., see Odaka, M. (210) 99
Koh, P.L., see Au, W.L. (209) 101
Kohriyama, T., see Ochi, K. (208) 43
Kohshi, K., Imada, H., Nomoto, S., Yamaguchi, R., Abe, H. and Yamamoto, H.
Successful treatment of radiation-induced brain necrosis by hyperbaric oxygen therapy (209) 115
Koizumi, K., see Hanyu, H. (209) 25
Kokubun, N., see Odaka, M. (211) 93
Kolb, S.J., Costello, F., Lee, A.G., White, M., Wong, S., Schwartz, E.D., Messé, S.R., Ellenbogen, J., Kasner, S.E. and Galetta, S.L.
Distinguishing ischemic stroke from the stroke-like lesions of MELAS using apparent diffusion coefficient mapping (216) 11
Kölmel, H.W., see Petereit, H.F. (206) 209
Komatsu, K.-i., Fukutake, T. and Hattori, T.
Fingertip photoplethysmography and migraine (216) 17
Komoto, J., see Miwa, H. (211) 85
Kondo, T., see Miwa, H. (211) 85

Kondo, T., see Morita, S. (216) 183
Kortenska, L., see Moyanova, S. (212) 59
Kosaka, K., see Katsuse, O. (211) 29
Kosaka, K., see Horimoto, Y. (216) 105
Koshino, Y., see Kobayashi, K. (208) 17
Kotorii, S., see Santa, Y. (212) 79
Kowa, H., see Nakaso, K. (207) 19
Koyama, S., see Itoh, T. (214) 7
Kramer, P.D., see Frohman, E.M. (210) 65
Krause, A., see Bryer, A. (216) 47
Krause, T., see Kassubek, J. (212) 85
Krishna, S., see Mancuso, M. (209) 61
Krivoshapkin, V.G., see Green, A.J.E. (212) 69
Kronenberg, M.F., see Kofler, M. (216) 67
Kuhlmann, T., see Brück, W. (206) 181
Kunishige, M., see Inoue, N. (210) 105
Kunkel, L.M., see Bönnemann, C.G. (206) 71
Kuntzer, T., Dunand, M., Schorderet, D.F., Vallat, J.-Michel., Hahn, A.F. and Bogousslavsky, J.
Phenotypic expression of a Pro 87 to Leu mutation in the connexin 32 gene in a large Swiss family with Charcot–Marie–Tooth neuropathy (207) 77
Kunzmann, V., see Seyfert, S. (206) 85
Kuo-Leblanc, V., see Salloway, S. (206) 115
Kupsky, W.J., see Petrov, T. (209) 31
Kurita, K., see Wada, M. (208) 67
Kuriyama, S., see Ikeguchi, M. (209) 41
Kuroda, Y., see Takashima, H. (207) 59
Kuroda, Y., see Inoue, N. (210) 105
Kuroda, Y., see Satoh, J.-i. (212) 11
Kuroda, Y., see Takashima, Y. (214) 37
Kurohara, K., see Satoh, J.-i. (212) 11
Kuroiwa, Y., see Johkura, K. (207) 1
Kuroiwa, Y., see Susuki, K. (211) 89
Kusumi, M., see Nakaso, K. (207) 19
Kuwabara, S., see Ogawara, K. (210) 41
Kuwabara, S., see Odaka, M. (211) 93
Kuwabara, S., see Ito, S. (216) 179
Kuwert, T., see Hilz, M.J. (216) 153

Lahat, N., see Shapiro, S. (206) 43
Lai, E.C., see Trail, M. (209) 79
Lam, W.W.M., see Mok, V.C.T. (216) 55
Larner, A.J., see Doran, M. (216) 127
Lassmann, H.
Hypoxia-like tissue injury as a component of multiple sclerosis lesions (206) 187
Latov, N., see Chin, R.L. (210) 19
Law, H.Y., see Wilder-Smith, E. (213) 25
Lazeron, R.H.C., Rombouts, S.A.R.B., de Sonneville, L., Barkhof, F. and Scheltens, P.
A paced visual serial addition test for fMRI (213) 29
Leary, S.M. and Thompson, A.J.
Interferon beta-1a in primary progressive multiple sclerosis (206) 215
Lee, A.G., see Kolb, S.J. (216) 11
Lee, C.K., see Lo, S.S. (214) 43
Lee, K.-S., see Kim, J.-S. (206) 31
Lee, K.-W., see Kim, N.-H. (206) 65
Leite, A.C.C., Mendonça, G.A.S., Serpa, M.J.A., Nascimento, O.J.M. and Araújo, Abelardo Q.-C.
Neurological manifestations in HTLV-I-infected blood donors (214) 49
Lenzi, C., see Annunziata, P. (213) 55
Leoh, T.H., see Lo, Y.L. (208) 105
Lerner, A., see Shapiro, S. (206) 43
Lewis, R.A., see Shah, J.R. (208) 113
LeWitt, P.A., see Lorenzl, S. (207) 71
Li, H., Wong, K.S. and Kay, R.
Relationship between the Oxfordshire Community Stroke Project classification and vascular abnormalities in patients with predominantly intracranial atherosclerosis (207) 65
Li, J., Gran, B., Zhang, G.-X., Ventura, E.S., Siglienti, I., Rostami, A. and Kamoun, M.
Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia (215) 95
Li, X., see Qin, W. (210) 35
Lim, M.S.F., see Au, W.L. (209) 101
Lim, T.C.C., see Au, W.L. (209) 101
Lin, J.-J., Yueh, K.-C., Chang, D.-C., Chang, C.-Y., Yeh, Y.-H. and Lin, S.-Z.
The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients (209) 87
Lin, S.-Z., see Lin, J.-J. (209) 87
Liu, W., see Qin, W. (210) 35
Liu, X.-y., see Zhuo, M. (216) 135
Lo, S.S., Hall, W.A., Cho, K.H., Orner, J., Lee, C.K. and Dusenbery, K.E.
Radiation dose response for supratentorial low-grade glioma—institutional experience and literature review (214) 43
Lo, Y.L., Leoh, T.H., Loh, L.M. and Tan, C.E.
Statin therapy and small fibre neuropathy: a serial electrophysiological study (208) 105
Locatelli, L., see Zivadinov, R. (210) 73
Loh, L.M., see Lo, Y.L. (208) 105
Loh, N.K., see Au, W.L. (209) 101
Lojkowska, W., Ryglewicz, D., Jedrzejczak, T., Minc, S., Jakubowska, T., Jarosz, H. and Bochynska, A.
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia (216) 119
Lopes, R., see Patti, F. (211) 55
Lopez, L., Cimadevilla, J.M., Aller, M.A., Arias, J., Nava, M.P. and Arias, J.L.
Diurnal locomotor activity and oxidative metabolism of the suprachiasmatic nucleus in two models of hepatic insufficiency (212) 93
Lorenzl, S., Albers, D.S., LeWitt, P.A., Chirichigno, J.W., Hilgenberg, S.L., Cudkowicz, M.E. and Beal, M.F.
Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases (207) 71
Lozano, R., see Barrachina, M. (215) 105
Lu, C.-S., see Wong, K.S. (216) 81
Lücking, C.H., see Kassubek, J. (212) 85
Lukas, C., see Hoffmann, V. (211) 81
Lum, S.Y., see Tan, E.-K. (216) 163
Lupi, M., see Rizzardini, M. (207) 51
Lycklama à Nijeholt, G. and Barkhof, F.
Differences between subgroups of MS: MRI findings and correlation with histopathology (206) 173

Macaskill, P., see Barnett, M.H. (213) 1
Madkour, O., see Elwan, O. (211) 15
Malcovati, L., see Appenzeller, O. (207) 37
Manconi, M., see Govoni, V. (216) 99
Mancuso, M., Filosto, M., Stevens, J.C., Patterson, M., Shanske, S., Krishna, S. and DiMauro, S.
Mitochondrial myopathy and complex III deficiency in a patient with a new stop-codon mutation (G339X) in the cytochrome *b* gene (209) 61
Mandal, S.K., see Misra, U.K. (208) 25
Manelfe, C., see Clanet, M. (206) 139
Mangolini, A., see Rizzardini, M. (207) 51
Mano, Y., see Kanno, M. (211) 5

Mantegazza, R., Baggi, F., Bernasconi, P., Antozzi, C., Confalonieri, P., Novellino, L., Spinelli, L., Ferrò, M.T., Beghi, E. and Cornelio, F.
Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up (212) 31
Marciani, M.G., see Tombini, M. (213) 83
Mareni, C., see Marini, V. (212) 75
Marín, J., see Servera, E. (209) 111
Marini, V., Ferrera, L., Dorcaratto, A., Viale, G., Origone, P., Mareni, C. and Garrè, C.
Identification of a novel *KRIT1* mutation in an Italian family with cerebral cavernous malformation by the protein truncation test (212) 75
Markovic, M., Trajkovic, V., Drulovic, J., Mesaros, S., Stojsavljevic, N., Dujmovic, I. and Stojkovic, M.M.
Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients (211) 67
Marui, W., see Katsuse, O. (211) 29
Mashimo, T., see Inoue, T. (211) 43
Mashimo, T., see Shibuta, S. (215) 31
Masters, C.L., see Green, A.J.E. (212) 69
Matsui, M., see Wang, H.-Y. (216) 61
Matsuki, T., see Numakura, C. (210) 61
Matsumine, H., see Kobayashi, T. (207) 11
Matsumoto, H., see Houzen, H. (211) 49
Matsumoto, M., see Kanno, M. (211) 5
Matsumoto, M., see Horimoto, Y. (216) 105
Matsumoto, T., see Inoue, N. (210) 105
Matsumoto, T., see Takashima, Y. (214) 37
Matsumura, T., see Tagawa, K. (211) 23
Matsushima, K., see Wang, H.-Y. (216) 61
Matsuyama, Z., Murase, M., Shimizu, H., Aoki, Y., Hayashi, M., Hozumi, I. and Inuzuka, T.
A novel insertion mutation of acetazolamide-responsive episodic ataxia in a Japanese family (210) 91
Mayer, S.A., see Claassen, J. (211) 37
Mayer, T.O. and Biller, J.
Antiplatelet prescribing patterns for TIA and ischemic stroke: the Indiana University experience (207) 5
McCombe, P., see Harness, J. (216) 33
McCombe, P.A., see Zhang, B. (212) 37
McCombe, P.A., see Athanasas-Platsis, S. (214) 27
McDougall, A.J. and McLeod, J.G.
Autonomic nervous system function in multiple sclerosis (215) 79
McLeod, J.G., see Barnett, M.H. (213) 1
McLeod, J.G., see McDougall, A.J. (215) 79
McMillan, C., see Halpern, C. (208) 31
McQuilty, R., see Pamphlett, R. (216) 95
Meisel, M., see Müller, T. (213) 61
Mendonça, G.A.S., see Leite, A.C.C. (214) 49
Merçon, M., see Puccioni-Sohler, M. (207) 87
Merkelbach, S., see Petereit, H.F. (206) 209
Mesaros, S., see Markovic, M. (211) 67
Messé, S.R., see Kolb, S.J. (216) 11
Metoki, N., see Sato, Y. (212) 55
Meyer, B.-U., see Gerwig, M. (215) 75
Miles, T.S., see Charlton, C.S. (208) 79
Miller, A., see Shapiro, S. (206) 43
Minami, M., see Ogata, A. (206) 79
Minc, S., see Lojkowska, W. (216) 119
Minematsu, K., see Saito, K. (210) 95
Minko, T., see Appenzeller, O. (207) 37
Minohara, M., see Ochi, H. (206) 109
Minohara, M., see Osoegawa, M. (209) 5
Miró, O., see Casademont, J. (206) 23
Misra, U.K., Kalita, J., Pandey, S. and Mandal, S.K.
Predictors of gastrointestinal bleeding in acute intracerebral haemorrhage (208) 25
Misra, U.K., see Kalita, J. (208) 109
Mitoma, H., Ishida, K., Shizuka-Ikeda, M. and Mizusawa, H.
Dual impairment of $GABA_A$- and $GABA_B$-receptor-mediated synaptic responses by autoantibodies to glutamic acid decarboxylase (208) 51
Mitsui, T., see Inoue, N. (210) 105
Mittelhamm, F., see Hecht, M.J. (213) 47
Miwa, H., Kajimoto, Y., Nakanishi, I., Morita, S., Komoto, J., Kihira, T. and Kondo, T.
T2-low signal intensity in the cortex in multiple system atrophy (211) 85
Miwa, H., see Morita, S. (216) 183
Mizuno, T., Takanashi, Y., Onodera, H., Shigeta, M., Tanaka, N., Yuya, H., Kitaichi, M. and Nakajima, K.
A case of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion with long clinical course and diffuse brain involvement (213) 67
Mizuno, Y., see Kobayashi, T. (207) 11
Mizusawa, H., see Mitoma, H. (208) 51
Mochi, M., Cevoli, S., Cortelli, P., Pierangeli, G., Scapoli, C., Soriani, S. and Montagna, P.
Investigation of an LDLR gene polymorphism (19p13.2) in susceptibility to migraine without aura (213) 7
Modrego, P.J. and Pina, M.A.
Trends in prevalence and incidence of multiple sclerosis in Bajo Aragón, Spain (216) 89
Mok, V., see Wong, K.S. (216) 81
Mok, V.C.T., Fan, Y.H., Lam, W.W.M., Hui, A.C.F. and Wong, K.S.
Small subcortical infarct and intracranial large artery disease in Chinese (216) 55
Momoo, T., see Johkura, K. (207) 1
Montagna, P., see Mochi, M. (213) 7
Monti, F., see Zivadinov, R. (210) 73
Monti-Bragadin, L., see Zivadinov, R. (216) 113
Moog, F.P. and Karenberg, A.
St. Francis came at dawn—the miraculous recovery of a hemiplegic monk in the Middle Ages (213) 15
Moore, P., see Halpern, C. (208) 31
Mori, E., see Ishii, K. (215) 71
Mori, M., see Ogawara, K. (210) 41
Mori, T., see Ishii, K. (215) 71
Morishita, M., see Horimoto, Y. (216) 105
Morita, S., see Miwa, H. (211) 85
Morita, S., Miwa, H., Kihira, T. and Kondo, T.
Cerebellar ataxia and leukoencephalopathy associated with cobalamin deficiency (216) 183
Morita, Y., Osaki, Y., Doi, Y., Forghani, B. and Gilden, D.H.
Chronic active VZV infection manifesting as zoster sine herpete, zoster paresis and myelopathy (212) 7
Morton, H., see Zhang, B. (212) 37
Morton, H., see Athanasas-Platsis, S. (214) 27
Morton, H., see Harness, J. (216) 33
Moser, A., Thümen, A. and Qadri, F.
Modulation of striatal serotonin and opioid receptor mRNA expression following systemic *N*-methyl-norsalsolinol administration (216) 109
Moser, E., see Kassubek, J. (212) 85
Mostafa, M., see Elwan, O. (211) 15
Moyanova, S., Kirov, R. and Kortenska, L.
Multi-unit activity suppression and sensorimotor deficits after endothelin-1-induced middle cerebral artery occlusion in conscious rats (212) 59
Mugnaini, F., see Annunziata, P. (213) 55
Müller, T., see Hoffmann, V. (211) 81
Müller, T., Meisel, M., Russ, H. and Przuntek, H.
Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients (213) 61
Munoz, D.G., see Kertesz, A. (206) 97

Murai, H., see Ochi, H. (206) 109
Murai, H., see Osoegawa, M. (209) 5
Murai, H., see Furuya, H. (209) 75
Murakami, T., see Ilieva, H. (215) 57
Murase, M., see Matsuyama, Z. (210) 91
Murray, J.D., see Swanson, K.R. (216) 1

Nagano, I., see Ilieva, H. (215) 57
Nagashima, K., see Ogata, A. (206) 79
Nagel, M. and Zangemeister, W.H.
The effect of transcranial magnetic stimulation over the cerebellum on the synkinesis of coordinated eye and head movements (213) 35
Nakajima, K., see Mizuno, T. (213) 67
Nakajima, M., see Saito, K. (210) 95
Nakamura, S., see Ochi, K. (208) 43
Nakamura, T., see Takashima, H. (207) 59
Nakamura, Y., see Inamasu, J. (209) 55
Nakanishi, I., see Miwa, H. (211) 85
Nakano, H., see Kobayashi, K. (208) 17
Nakashima, K., see Nakaso, K. (207) 19
Nakaso, K., Yasui, K., Kowa, H., Kusumi, M., Ueda, K., Yoshimoto, Y., Takeshima, T., Sasaki, K. and Nakashima, K.
Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype (207) 19
Nakazawa, H., see Horimoto, Y. (216) 105
Nalini, A., see Gourie-Devi, M. (209) 13
Nascimento, O.J.M., see Leite, A.C.C. (214) 49
Nasuelli, D., see Zivadinov, R. (210) 73
Nasuelli, D., see Zivadinov, R. (216) 113
Nava, M.P., see Lopez, L. (212) 93
Navarro, C., see Seijo-Martínez, M. (208) 87
Nelson, N.D., see Trail, M. (209) 79
Neundörfer, B., see Brown, C.M. (208) 71
Neundörfer, B., see Hecht, M.J. (213) 47
Neundörfer, B., see Hilz, M.J. (216) 153
Newman, N.J., see Thambisetty, M. (208) 93
Ng, I., see Wilder-Smith, E. (213) 25
Nguyen, K.B., see Zhang, B. (212) 37
Nguyen, L.T., Ramanathan, M., Weinstock-Guttman, B., Baier, M., Brownscheidle, C. and Jacobs, L.D.
Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients (209) 93
Niehaus, L., see Gerwig, M. (215) 75
Niino, M., see Houzen, H. (211) 49
Nishikawa, T., see Ogawa, M. (210) 53
Nishimura, M., see Inoue, T. (211) 43
Nishino, I., see Tagawa, K. (211) 23
Nishiyama, Y., see Ikeguchi, M. (209) 41
Nishiyama, Y., see Sakamaki, M. (209) 69
Nogoshi, S., see Houzen, H. (211) 49
Nomoto, S., see Kohshi, K. (209) 115
Nonaka, I., see Tagawa, K. (211) 23
Nora, D.B., see Gomes, I. (214) 21
Novellino, L., see Mantegazza, R. (212) 31
Numakura, C., Shirahata, E., Yamashita, S., Kanai, M., Kijima, K., Matsuki, T. and Hayasaka, K.
Screening of the early growth response 2 gene in Japanese patients with Charcot–Marie–Tooth disease type 1 (210) 61
Nunes, R.G., see de Freitas, G.R. (210) 31

Ochi, H., Murai, H., Osoegawa, M., Minohara, M., Inaba, S. and Kira, J.-i.
Juvenile muscular atrophy of distal upper extremity associated with airway allergy: Two cases successfully treated by plasma exchange (206) 109
Ochi, H., see Osoegawa, M. (209) 5
Ochi, K., Kohriyama, T., Higaki, M., Ikeda, J., Harada, A. and Nakamura, S.
Changes in serum macrophage-related factors in patients with chronic inflammatory demyelinating polyneuropathy caused by intravenous immunoglobulin therapy (208) 43
Oda, S., see Ito, S. (216) 179
Odaka, M., Koga, M., Yuki, N., Susuki, K. and Hirata, K.
Longitudinal changes of anti-ganglioside antibodies before and after Guillain–Barré syndrome onset subsequent to *Campylobacter jejuni* enteritis (210) 99
Odaka, M., Yuki, N., Kokubun, N., Hirata, K. and Kuwabara, S.
Axonal Guillain–Barré syndrome associated with axonal Charcot–Marie–Tooth disease (211) 93
Ogata, A., Hamaue, N., Terado, M., Minami, M., Nagashima, K. and Tashiro, K.
Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus (206) 79
Ogawa, M., Shigeto, H., Yamamoto, T., Oya, Y., Wada, K., Nishikawa, T. and Kawai, M.
D-Cycloserine for the treatment of ataxia in spinocerebellar degeneration (210) 53
Ogawa, M., see Tagawa, K. (211) 23
Ogawara, K., Kuwabara, S., Koga, M., Mori, M., Yuki, N. and Hattori, T.
Anti-GM1b IgG antibody is associated with acute motor axonal neuropathy and *Campylobacter jejuni* infection (210) 41
Ohkawa, M., see Ikeguchi, M. (209) 41
Ohnishi, Y., see Inoue, N. (210) 105
Ohyagi, Y., see Furuya, H. (209) 75
Okada, Y., see Hagiwara, N. (212) 99
Okada, Y., see Kishikawa, K. (213) 19
Okada, Y., see Irie, F. (215) 115
Okamoto, K., see Inoue, C. (215) 119
Oki, T., see Ito, S. (216) 179
Onai, N., see Wang, H.-Y. (216) 61
Ono, S., see Wada, M. (208) 67
Onodera, H., see Mizuno, T. (213) 67
Origone, P., see Marini, V. (212) 75
Orner, J., see Lo, S.S. (214) 43
Osaki, Y., see Morita, Y. (212) 7
Osakovsky, V.L., see Green, A.J.E. (212) 69
Osame, M., see Kiwaki, T. (206) 17
Osame, M., see Umehara, F. (215) 111
Oshima, Y., see Inoue, N. (210) 105
Osoegawa, M., see Ochi, H. (206) 109
Osoegawa, M., Ochi, H., Minohara, M., Murai, H., Umehara, F., Furuya, H., Yamada, T. and Kira, J.-i.
Myelitis with atopic diathesis: a nationwide survey of 79 cases in Japan (209) 5
O'Suilleabhain, P., see Frohman, E.M. (210) 65
Otsuki, M., see Tamura, I. (209) 19
Oya, Y., see Ogawa, M. (210) 53

Palace, J.
Clinical and laboratory characteristics of secondary progressive MS (206) 131
Palau, F., see Seijo-Martínez, M. (208) 87
Palermo, F., see Patti, F. (211) 55
Pamphlett, R., Todd, E., Vink, R., McQuilty, R. and Cheema, S.S.
Magnesium supplementation does not delay disease onset or increase survival in a mouse model of familial ALS (216) 95
Pandey, S., see Misra, U.K. (208) 25
Paolillo, A., see Bellomi, F. (215) 3
Papageorgiou, C., see Paraskevas, G.P. (215) 51

Paraskevas, G.P., Kapaki, E., Petropoulou, O., Anagnostouli, M., Vagenas, V. and Papageorgiou, C.
Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism (215) 51
Parry, G.J., see Walk, D. (214) 3
Patel, H., see Wilkinson, P.A. (216) 43
Patterson, M., see Mancuso, M. (209) 61
Patti, F., Cacopardo, M., Palermo, F., Ciancio, M.R., Lopes, R., Restivo, D. and Reggio, A.
Health-related quality of life and depression in an Italian sample of multiple sclerosis patients (211) 55
Pauli, E., see Hammen, (215) 21
Pauli, E., see Hilz, M.J. (216) 153
Pavanni, R., see Tan, E.-K. (216) 163
Peasley, M.A. and Shi, R.
Ischemic insult exacerbates acrolein-induced conduction loss and axonal membrane disruption in guinea pig spinal cord white matter (216) 23
Pérez, D., see Servera, E. (209) 111
Petereit, H.F., Pukrop, R., Fazekas, F., Bamborschke, S.U., Röpele, S., Kölmel, H.W., Merkelbach, S., Japp, G., Jongen, P.J.H., Hartung, H.P. and Hommes, O.R.
Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis (206) 209
Petropoulou, O., see Paraskevas, G.P. (215) 51
Petrov, T., Rafols, J.A., Alousi, S.S., Kupsky, W.J., Johnson, R., Shah, J., Shah, A. and Watson, C.
Cellular compartmentalization of phosphorylated eIF2α and neuronal NOS in human temporal lobe epilepsy with hippocampal sclerosis (209) 31
Petzold, A., see Rejdak, K. (208) 1
Pierangeli, G., see Mochi, M. (213) 7
Pimenta, G., see Puccioni-Sohler, M. (207) 87
Pina, M.A., see Modrego, P.J. (216) 89
Pinto, F., see Irony-Tur-Sinai, M. (206) 49
Placidi, F., see Tombini, M. (213) 83
Platonov, F.A., see Green, A.J.E. (212) 69
Platsch, G., see Hilz, M.J. (216) 153
Pöhlau, D., see Hoffmann, V. (211) 81
Polman, C., see 't Hart, B.A. (212) 21
Poon, P.W.F., see Chiu, T.W. (216) 143
Pozharov, V., see Appenzeller, O. (207) 37
Pozzilli, C., see Bellomi, F. (215) 3
Pradeep Kumar, S., see Sylaja, P.N. (215) 9
Pruim, J., see Schaafsma, A. (210) 23
Przuntek, H., see Hoffmann, V. (211) 81
Przuntek, H., see Müller, T. (213) 61
Puccioni-Sohler, M., Chimelli, L., Merç on, M., Gonç alves, R.R., Pimenta, G., Bianco, C., Rios, M. and Jacobson, S.
Pathological and virological assessment of acute HTLV-I-associated myelopathy complicated with encephalopathy and systemic inflammation (207) 87
Pukrop, R., see Petereit, H.F. (206) 209
Puli, S.R., see Bermel, R.A. (208) 57

Qadri, F., see Moser, A. (216) 109
Qin, W., Zhang, T., Han, J., Tang, L., Li, X., Feng, G., Liu, W. and He, L.
A novel insertion mutation in spastin gene is the cause of spastic paraplegia in a Chinese family (210) 35

Radhakrishnan, K., see Sylaja, P.N. (215) 9
Rafols, J.A., see Petrov, T. (209) 31
Ramanathan, M., see Nguyen, L.T. (209) 93
Ramesar, R., see Bryer, A. (216) 47
Ranjan, P., see Kalita, J. (208) 109
Rascol, O., see Vidal, R. (207) 110
Rauschka, H., Retzl, J., Baumhackl, U., Bankl, H.C., Salomonowitz, E. and Schmidbauer, M.
Subacute brainstem angioencephalopathy: a case report and review of the literature (208) 101
Reggio, A., see Patti, F. (211) 55
Regidor, I., see Cid, C. (206) 91
Reimann, J., see Bönnemann, C.G. (206) 71
Rejdak, K., Petzold, A., Sharpe, M.A., Smith, M., Keir, G., Stelmasiak, Z., Thompson, E.J. and Giovannoni, G.
Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury (208) 1
Restivo, D., see Patti, F. (211) 55
Retzl, J., see Rauschka, H. (208) 101
Ridding, M.C., see Charlton, C.S. (208) 79
Rios, M., see Puccioni-Sohler, M. (207) 87
Rizzardini, M., Lupi, M., Bernasconi, S., Mangolini, A. and Cantoni, L.
Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid (207) 51
Rocca, M.A., see Holtmannspötter, M. (206) 27
Rocca, M.A., see Horsfield, M.A. (216) 169
Rodnitzky, R.L., see Uc, E.Y. (212) 1
Rodriguez-Santiago, B., see Casademont, J. (206) 23
Rombouts, S.A.R.B., see Lazeron, R.H.C. (213) 29
Röpele, S., see Petereit, H.F. (206) 209
Romigi, A., see Tombini, M. (213) 83
Rosenberg, C., see Salloway, S. (206) 115
Rossi, P., see Horsfield, M.A. (216) 169
Rostami, A., see Li, J. (215) 95
Rovaris, M., see Holtmannspötter, M. (206) 27
Rovaris, M., see Horsfield, M.A. (216) 169
Rugilo, C., see Bendersky, M. (211) 75
Russ, H., see Müller, T. (213) 61
Ryglewicz, D., see Lojkowska, W. (216) 119

Sadanaga-Akiyoshi, F., see Takashima, Y. (214) 37
Saida, T., see Wang, H.-Y. (216) 61
Saito, K., Kimura, K., Minematsu, K., Shiraishi, A. and Nakajima, M.
Transient global amnesia associated with an acute infarction in the retrosplenium of the corpus callosum (210) 95
Sakakibara, R., see Ito, S. (216) 179
Sakamaki, M., Igarashi, H., Nishiyama, Y., Hagiwara, H., Ando, J., Chishiki, T., Curran, B.C. and Katayama, Y.
Effect of glycerol on ischemic cerebral edema assessed by magnetic resonance imaging (209) 69
Sakaue, G., see Inoue, T. (211) 43
Sakazume, Y., see Inoue, C. (215) 119
Salinas, M., see Cid, C. (206) 91
Salloway, S., Gur, T., Berzin, T., Tavares, R., Zipser, B., Correia, S., Hovanesian, V., Fallon, J., Kuo-Leblanc, V., Glass, D., Hulette, C., Rosenberg, C., Vitek, M. and Stopa, E.
Corrigendum to "Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease" [J. Neurol. Sci. 203–204 (2002) 183–187] (206) 115
Salomonowitz, E., see Rauschka, H. (208) 101
Saltuari, L., see Kofler, M. (216) 67
Sancho, J., see Servera, E. (209) 111
Sander, H.W., see Chin, R.L. (210) 19
Sankara Sarma, P., see Sylaja, P.N. (215) 9
Santa, Y., Uyama, E., Chui, D.H., Arima, M., Kotorii, S., Takahashi, K. and Tabira, T.
Genetic, clinical and pathological studies of CADASIL in Japan: a partial contribution of Notch3 mutations and implications of smooth muscle cell degeneration for the pathogenesis (212) 79
Sasaki, K., see Nakaso, K. (207) 19
Sasaki, K., see Kobayashi, K. (208) 17

Sato, Y., Kaji, M., Metoki, N., Yoshida, H. and Satoh, K.
Coagulation–fibrinolysis abnormalities in patients receiving antiparkinsonian agents (212) 55
Satoh, J.-i., see Takashima, H. (207) 59
Satoh, J.-i., Yukitake, M., Kurohara, K., Takashima, H. and Kuroda, Y.
Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis (212) 11
Satoh, K., see Sato, Y. (212) 55
Scagnolari, C., see Bellomi, F. (215) 3
Scapoli, C., see Mochi, M. (213) 7
Schaafsma, A., de Jong, B.M., Bams, J.L., Haaxma-Reiche, H., Pruim, J. and Zijlstra, J.G.
Cerebral perfusion and metabolism in resuscitated patients with severe post-hypoxic encephalopathy (210) 23
Schaafsma, J.D., Giladi, N., Balash, Y., Bartels, A.L., Gurevich, T. and Hausdorff, J.M.
Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa (212) 47
Schäfer, I., see Hammen, (215) 21
Schalepfer, W.W., see Jacobs, D.A. (213) 77
Scheltens, P., see Lazeron, R.H.C. (213) 29
Schenck, J.F.
Magnetic resonance imaging of brain iron (207) 99
Schimrigk, S., see Hoffmann, V. (211) 81
Schmidbauer, M., see Rauschka, H. (208) 101
Schorderet, D.F., see Kuntzer, T. (207) 77
Schröder, R., see Bönnemann, C.G. (206) 71
Schuster, G., see Bendersky, M. (211) 75
Schwartz, E.D., see Kolb, S.J. (216) 11
Schwartz, I.V.D., see Gomes, I. (214) 21
Schwartz, M., see Jeppesen, T.D. (214) 17
Secades, J., see Barrachina, M. (215) 105
Seijo-Martínez, M., Castro del Río, M., Campos, Y., Palau, F., Arenas, J., Teijeira, S., Fernández Hojas, R. and Navarro, C.
Unusual clinical findings and Complex III deficiency in a family with myotonic dystrophy (208) 87
Seijo-Martínez, M., Castro del Río, M., Fontoira, E. and Fontoira, M.
Acute femoral neuropathy secondary to an iliacus muscle hematoma (209) 119
Seow, D.C.C., see Au, W.L. (209) 101
Serpa, M.J.A., see Leite, A.C.C. (214) 49
Servera, E., Sancho, J., Gómez-Merino, E., Briones, M.L., Vergara, P., Pérez, D. and Marín, J.
Non-invasive management of an acute chest infection for a patient with ALS (209) 111
Seyfert, S., Koch, H.C. and Kunzmann, V.
Conditions of iodine contrast transfer from lumbosacral CSF to blood (206) 85
Shah, A., see Petrov, T. (209) 31
Shah, J., see Petrov, T. (209) 31
Shah, J.R. and Lewis, R.A.
Sarcoidosis of the cauda equina mimicking Guillain–Barré syndrome (208) 113
Shan, D.-E., see Wong, K.S. (216) 81
Shanske, S., see Mancuso, M. (209) 61
Shapiro, S., Miller, A., Lahat, N., Sobel, E. and Lerner, A.
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis (206) 43
Sharma, J., see Bermel, R.A. (208) 57
Sharpe, M.A., see Rejdak, K. (208) 1
Shatunov, A., see Green, A.J.E. (212) 69
Shen, H., see Tan, E.-K. (216) 163
Sherman, W.H., see Chin, R.L. (210) 19
Shi, R., see Peasley, M.A. (216) 23
Shibata, M., see Inoue, T. (211) 43
Shibata, S.C., see Inoue, T. (211) 43
Shibuta, S., Varathan, S. and Mashimo, T.
The neuroprotective effect of ONO-1714 on NMDA-mediated cytotoxicity in vitro (215) 31
Shigeta, M., see Mizuno, T. (213) 67
Shigeto, H., see Ogawa, M. (210) 53
Shimazaki, M., see Kobayashi, K. (208) 17
Shimizu, H., see Matsuyama, Z. (210) 91
Shimuzu, T., see Hanyu, H. (209) 25
Shiote, M., see Ilieva, H. (215) 57
Shirahata, E., see Numakura, C. (210) 61
Shiraishi, A., see Saito, K. (210) 95
Shizuka-Ikeda, M., see Mitoma, H. (208) 51
Shoji, M., see Ilieva, H. (215) 57
Shoji, S., see Yoshizawa, T. (215) 45
Sica, R.E.P., see Bendersky, M. (211) 75
Sicsic, C., see Irony-Tur-Sinai, M. (206) 49
Siglienti, I., see Li, J. (215) 95
Sivtseva, T.M., see Green, A.J.E. (212) 69
Skinner, R.D., see Uc, E.Y. (212) 1
Slowik, A., Iskra, T., Turaj, W., Hartwich, J., Dembinska-Kiec, A. and Szczudlik, A.
LDL phenotype B and other lipid abnormalities in patients with large vessel disease and small vessel disease (214) 11
Smith, M., see Rejdak, K. (208) 1
Sobel, E., see Shapiro, S. (206) 43
Sobue, G., see Ito, Y. (209) 105
Sorensen, P.S.
The role of intravenous immunoglobulin in the treatment of multiple sclerosis (206) 123
Soriani, S., see Mochi, M. (213) 7
Sperli, F., see Tombini, M. (213) 83
Spijksma, G., see 't Hart, B.A. (212) 21
Spinelli, L., see Mantegazza, R. (212) 31
Spreer, J., see Kassubek, J. (212) 85
Srivastava, R.A.K.
Scavenger receptor class B type I expression in murine brain and regulation by estrogen and dietary cholesterol (210) 11
Stadelmann, C., see Brück, W. (206) 181
Steck, A.J., see Fluri, F. (207) 43
Stecker, M.M., see Jacobs, D.A. (213) 77
Stefan, H., see Hammen, (215) 21
Stefan, H., see Hilz, M.J. (216) 153
Stelmasiak, Z., see Rejdak, K. (208) 1
Stevens, J.C., see Mancuso, M. (209) 61
Stival, B., see Zivadinov, R. (210) 73
Stojkovic, M.M., see Markovic, M. (211) 67
Stojsavljevic, N., see Markovic, M. (211) 67
Stopa, E., see Salloway, S. (206) 115
Sugimori, K., see Kobayashi, K. (208) 17
Sugimoto, K., see Ito, S. (206) 39
Sun, L.-y., see Zhuo, M. (216) 135
Susuki, K., see Odaka, M. (210) 99
Susuki, K., Johkura, K., Yuki, N. and Kuroiwa, Y.
Clinical deterioration in Bickerstaff's brainstem encephalitis caused by overlapping Guillain-Barré syndrome (211) 89
Suzuki, T., see Ito, Y. (209) 105
Swanson, K.R., Bridge, C., Murray, J.D. and Alvord Jr ,E.C.
Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion (216) 1
Swash, M., see de Carvalho, M. (210) 83
Sylaja, P.N., Ahsan Moosa, N.V., Radhakrishnan, K., Sankara Sarma, P. and Pradeep Kumar, S.
Differential diagnosis of patients with intracranial sinus venous thrombosis related isolated intracranial hypertension from those with idiopathic intracranial hypertension (215) 9
Szczudlik, A., see Slowik, A. (214) 11

Tabira, T., see Santa, Y. (212) 79
Tagawa, K., Ogawa, M., Kawabe, K., Yamanaka, G., Matsumura, T., Goto, K., Nonaka, I., Nishino, I. and Hayashi, Y.K.
Protein and gene analyses of dysferlinopathy in a large group of Japanese muscular dystrophy patients (211) 23
Takada, F., see Bönnemann, C.G. (206) 71
Takahashi, A., see Kato, H. (208) 9
Takahashi, K., see Santa, Y. (212) 79
Takanashi, Y., see Mizuno, T. (213) 67
Takasaki, M., see Hanyu, H. (209) 25
Takashima, H., Eriguchi, M., Nakamura, T., Satoh, J.-i., Kuroda, Y., Udono, H. and Uchino, A.
Interferon therapy-responsive brain metabolic abnormalities in a case of adult-onset subacute sclerosing panencephalitis evaluated by $^{1}$H MRS analysis (207) 59
Takashima, H., see Satoh, J.-i. (212) 11
Takashima, Y., Yao, H., Koga, H., Endo, K., Matsumoto, T., Uchino, A., Sadanaga-Akiyoshi, F., Yuzuriha, T. and Kuroda, Y.
Frontal lobe dysfunction caused by multiple lacunar infarction in community-dwelling elderly subjects (214) 37
Takenoshita, M., see Inoue, T. (211) 43
Takeshima, T., see Nakaso, K. (207) 19
Takeuchi, H., see Ikeguchi, M. (209) 41
Tamura, I., Kikuchi, S., Otsuki, M., Kitagawa, M. and Tashiro, K.
Deficits of working memory during mental calculation in patients with Parkinson's disease (209) 19
Tan, C., see Tan, E.-K. (216) 163
Tan, C.E., see Lo, Y.L. (208) 105
Tan, E.K., see Wilder-Smith, E. (213) 25
Tan, E.-K., Tan, C., Fook-Chong, S.M.C., Lum, S.Y., Chai, A., Chung, H., Shen, H., Zhao, Y., Teoh, M.L., Yih, Y., Pavanni, R., Chandran, V.R. and Wong, M.C.
Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese (216) 163
Tan, I.K., see Au, W.L. (209) 101
Tanaka, K., see Furuya, H. (209) 75
Tanaka, M., see Inoue, C. (215) 119
Tanaka, N., see Mizuno, T. (213) 67
Tanaka, Y., see Hanyu, H. (209) 25
Tang, L., see Qin, W. (210) 35
Tashiro, K., see Ogata, A. (206) 79
Tashiro, K., see Tamura, I. (209) 19
Tashiro, K., see Houzen, H. (211) 49
Tavares, R., see Salloway, S. (206) 115
Teijeira, S., see Seijo-Martínez, M. (208) 87
Tel, E., see Durmaz, R. (215) 87
Teoh, M.L., see Tan, E.-K. (216) 163
Terado, M., see Ogata, A. (206) 79
Terasawa, K.-j., see Furuya, H. (209) 75
't Hart, B.A., Vogels, J.T.W.E., Spijksma, G., Brok, H.P.M., Polman, C. and van der Greef, J.
$^{1}$H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease (212) 21
the Promise Study Group, see Wolinsky, J.S. (206) 145
Thambisetty, M., Biousse, V. and Newman, N.J.
Hypertensive brainstem encephalopathy: clinical and radiographic features (208) 93
Thompson, A.J., see Leary, S.M. (206) 215
Thompson, E.J., see Rejdak, K. (208) 1
Thompson, P.D., see Charlton, C.S. (208) 79
Thompson, T.G., see Bönnemann, C.G. (206) 71
Thümen, A., see Moser, A. (216) 109
Tjoa, C.W., see Bermel, R.A. (208) 57
Tobimatsu, S., see Arakawa, K. (207) 31
Tobisawa, M. and Yamaguchi, M.
Inhibitory role of regucalcin in the regulation of nitric oxide synthase activity in rat brain cytosol: involvement of aging (209) 47
Todd, E., see Pamphlett, R. (216) 95
Togashi, H., see Kanno, M. (211) 5
Tomandl, B., see Hammen, (215) 21
Tomassini, V., see Bellomi, F. (215) 3
Tombini, M., Marciani, M.G., Romigi, A., Izzi, F., Sperli, F., Bozzao, A., Floris, R., De Simone, R. and Placidi, F.
Bilateral frontal polymicrogyria and epilepsy in a patient with Turner mosaicism: a case report (213) 83
Tomi, H., see Arakawa, K. (207) 31
Tommasi, M.A., see Zivadinov, R. (210) 73
Tommasi, M.A., see Zivadinov, R. (216) 113
Touge, T., see Ikeguchi, M. (209) 41
Toyoda, K., see Hagiwara, N. (212) 99
Toyoda, K., see Irie, F. (215) 115
Trail, M., Nelson, N.D., Van, J.N., Appel, S.H. and Lai, E.C.
A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options (209) 79
Trajkovic, V., see Markovic, M. (211) 67
Trapp, B.D., see Bjartmar, C. (206) 165
Tsoi, T.H., see Wong, K.S. (216) 81
Turaj, W., see Slowik, A. (214) 11
Turkman, A., see de Carvalho, M. (210) 83
Turnbull, D.M., see Chinnery, P.F. (211) 63

Uc, E.Y., Skinner, R.D., Rodnitzky, R.L. and Garcia-Rill, E.
The midlatency auditory evoked potential P50 is abnormal in Huntington's disease (212) 1
Uchino, A., see Takashima, H. (207) 59
Uchino, A., see Takashima, Y. (214) 37
Uda, K., see Irie, F. (215) 115
Udono, H., see Takashima, H. (207) 59
Ueda, K., see Nakaso, K. (207) 19
Umehara, F., see Kiwaki, T. (206) 17
Umehara, F., see Osoegawa, M. (209) 5
Umehara, F., Yoshino, S., Arimura, Y., Fukuoka, T., Arimura, K. and Osame, M.
Posterior interosseous nerve syndrome with hourglass-like fascicular constriction of the nerve (215) 111
Uyama, E., see Santa, Y. (212) 79

Vagenas, V., see Paraskevas, G.P. (215) 51
Valenzuela, R.M., see Chen, M. (215) 37
Vallat, J.-Michel., see Kuntzer, T. (207) 77
Van der Greef, J., see 't Hart, B.A. (212) 21
Van der Ven, P.F.M., see Bönnemann, C.G. (206) 71
Van, J.N., see Trail, M. (209) 79
Varathan, S., see Shibuta, S. (215) 31
Ventura, E.S., see Li, J. (215) 95
Vergara, P., see Servera, E. (209) 111
Viale, G., see Marini, V. (212) 75
Vidal, R., Delisle, M.B., Rascol, O. and Ghetti, B.
Hereditary ferritinopathy (207) 110
Viedma, P., see Casademont, J. (206) 23
Vincent, M., see de Freitas, G.R. (210) 31
Vink, R., see Pamphlett, R. (216) 95
Vissing, J., see Jeppesen, T.D. (214) 17
Vitek, M., see Salloway, S. (206) 115
Vladimirtsev, V.A., see Green, A.J.E. (212) 69
Vlodavsky, I., see Irony-Tur-Sinai, M. (206) 49
Vogels, J.T.W.E., see 't Hart, B.A. (212) 21

Vollmers, B., see Bönnemann, C.G. (206) 71
Vukusic, S. and Confavreux, C.
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis (206) 135
Vukusic, S. and Confavreux, C.
Primary and secondary progressive multiple sclerosis (206) 153

Wada, K., see Ogawa, M. (210) 53
Wada, M., Ono, S., Kadoya, T., Kawanami, T., Kurita, K. and Kato, T.
Decreased galectin-1 immunoreactivity of the skin in amyotrophic lateral sclerosis (208) 67
Walk, D., Zaretskaya, M. and Parry, G.J.
Symptom duration and clinical features in painful sensory neuropathy with and without nerve conduction abnormalities (214) 3
Walsh, M.D., see Zhang, B. (212) 37
Wang, D.-S., see Cheng, Q. (215) 63
Wang, H.-Y., Matsui, M., Araya, S.-i., Onai, N., Matsushima, K. and Saida, T.
Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis (216) 61
Wang, W.-Z., see Cheng, Q. (215) 63
Warlo, I., see Bönnemann, C.G. (206) 71
Warner, T.T., see Wilkinson, P.A. (216) 43
Watanabe, M., see Yoshizawa, T. (215) 45
Watson, C., see Petrov, T. (209) 31
Wayne Moore, G.R.
MRI-clinical correlations: more than inflammation alone-what can MRI contribute to improve the understanding of pathological processes in MS? (206) 175
Weinstock-Guttman, B., see Nguyen, L.T. (209) 93
Werner, D., see Hecht, M.J. (213) 47
White, M., see Kolb, S.J. (216) 11
Wibrand, F., see Jeppesen, T.D. (214) 17
Wilder-Smith, E., Tan, E.K., Law, H.Y., Zhao, Y., Ng, I. and Wong, M.C.
Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family (213) 25
Wilkinson, P.A., Hart, P.E., Patel, H., Warner, T.T. and Crosby, A.H.
SPG3A mutation screening in English families with early onset autosomal dominant hereditary spastic paraplegia (216) 43
Will, K.M., see Deschenes, M.R. (210) 5
Williams, D.B., see Barnett, M.H. (213) 1
Wilson, R.B.
Frataxin and frataxin deficiency in Friedreich's ataxia (207) 103
Wirguin, I., see Ifergane, G. (213) 11
Wolinsky, J.S., and the Promise Study Group
The diagnosis of primary progressive multiple sclerosis (206) 145
Wong, K.S., see Li, H. (207) 65
Wong, K.S., see Mok, V.C.T. (216) 55
Wong, K.S., Lu, C.-S., Shan, D.-E., Yang, C.-C., Tsoi, T.H. and Mok, V.
Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease (216) 81
Wong, M.C., see Wilder-Smith, E. (213) 25
Wong, M.C., see Tan, E.-K. (216) 163
Wong, S., see Kolb, S.J. (216) 11
Wujek, J.R., see Bjartmar, C. (206) 165

Xu, D.-h., see Zhuo, M. (216) 135

Yahara, O., see Itoh, T. (214) 7
Yamada, T., see Osoegawa, M. (209) 5
Yamaguchi, M., see Tobisawa, M. (209) 47
Yamaguchi, R., see Kohshi, K. (209) 115
Yamamoto, H., see Kohshi, K. (209) 115
Yamamoto, T., see Ogawa, M. (210) 53
Yamamoto, T., see Horimoto, Y. (216) 105
Yamanaka, G., see Tagawa, K. (211) 23
Yamashita, S., see Numakura, C. (210) 61
Yang, C.-C., see Wong, K.S. (216) 81
Yang, D.-W., see Kim, J.-S. (206) 31
Yao, H., see Takashima, Y. (214) 37
Yasuda, M., see Furuya, H. (209) 75
Yasuda, T., see Ito, Y. (209) 105
Yasui, K., see Nakaso, K. (207) 19
Yee, W.C., see Au, W.L. (209) 101
Yeh, Y.-H., see Lin, J.-J. (209) 87
Yew, D.T.W., see Chiu, T.W. (216) 143
Yih, Y., see Tan, E.-K. (216) 163
Yokokawa, Y., see Ito, Y. (209) 105
Yoshida, H., see Sato, Y. (212) 55
Yoshida, S., see Inoue, N. (210) 105
Yoshimoto, Y., see Nakaso, K. (207) 19
Yoshino, H., see Inoue, N. (210) 105
Yoshino, S., see Umehara, F. (215) 111
Yoshioka, M., see Kanno, M. (211) 5
Yoshizawa, T., Watanabe, M., Frusho, K. and Shoji, S.
Magnetic resonance imaging demonstrates differential atrophy of pontine base and tegmentum in Machado–Joseph disease (215) 45
Yu, F.-r., see Zhuo, M. (216) 135
Yuasa, H., see Horimoto, Y. (216) 105
Yueh, K.-C., see Lin, J.-J. (209) 87
Yuki, N., see Ogawara, K. (210) 41
Yuki, N., see Odaka, M. (210) 99
Yuki, N., see Susuki, K. (211) 89
Yuki, N., see Odaka, M. (211) 93
Yukitake, M., see Satoh, J.-i. (212) 11
Yuya, H., see Mizuno, T. (213) 67
Yuzuriha, T., see Takashima, Y. (214) 37

Zangemeister, W.H., see Nagel, M. (213) 35
Zaretskaya, M., see Walk, D. (214) 3
Zeidler, M., see Green, A.J.E. (212) 69
Zhang, B., Walsh, M.D., Nguyen, K.B., Hillyard, N.C., Cavanagh, A.C., McCombe, P.A. and Morton, H.
Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed-type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice (212) 37
Zhang, B., see Athanasas-Platsis, S. (214) 27
Zhang, G.-X., see Li, J. (215) 95
Zhang, J., see Kobayashi, T. (207) 11
Zhang, T., see Qin, W. (210) 35
Zhang, Y., see Cheng, Q. (215) 63
Zhao, Y., see Wilder-Smith, E. (213) 25
Zhao, Y., see Tan, E.-K. (216) 163
Zhou, Y., see Brannagan III ,T.H. (208) 39
Zhuo, M., Yu, F.-r., Xu, D.-h., Sun, L.-y. and Liu, X.-y.
Baculovirus *p35* gene greatly enhances PC12 cell's resistance against oxidative stress (216) 135
Zijlstra, J.G., see Schaafsma, A. (210) 23
Zipser, B., see Salloway, S. (206) 115
Zivadinov, R., Zorzon, M., Locatelli, L., Stival, B., Monti, F., Nasuelli, D., Tommasi, M.A., Bratina, A. and Cazzato, G.
Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study (210) 73
Zivadinov, R., Zorzon, M., Tommasi, M.A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L. and Cazzato, G.
A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a (216) 113
Zorzon, M., see Zivadinov, R. (210) 73
Zorzon, M., see Zivadinov, R. (216) 113

ELSEVIER

Journal of the Neurological Sciences 216 (2003) 207–213

Journal of the Neurological Sciences

www.elsevier.com/locate/jns

# Cumulative Subject Index, Volumes 206–216 (2003)

A Japanese family (210) 91
ABCA1 (210) 11
Acetazolamide (210) 91
Active neuromuscular stimulation (215) 13
Acute disseminated encephalomyelitis (206) 27
Acute inflammatory demyelinating polyneuropathy (210) 105
Acute motor axonal neuropathy (210) 41, (211) 93
Adhesion molecule (215) 119
Adhesion molecules (212) 37
Adult-onset (207) 59
A-δ fibers (216) 67
Age (209) 25
Aging (207) 37, (209) 47, (214) 37, (216) 143
AIDS (208) 39
Airway secretions management (209) 111
ALS treatment (209) 111
Alterated splice site (212) 75
Alzheimer's disease (208) 17, (208) 31, (209) 25, (210) 11, (215) 71, (216) 119, (216) 127
Alzheimer's disease (AD) (216) 105
21-Aminosteroids (215) 87
AMPA/kainate receptor (206) 91
Amyotrophic lateral sclerosis (206) 65, (206) 91, (207) 51, (208) 67, (209) 79, (210) 83, (211) 85, (213) 47, (216) 95
Amyotrophic lateral sclerosis (ALS) (215) 57
Anatomy (211) 75
Anesthesia (211) 43
Angiocentric immunoproliferative lesions (213) 67
Angioencephalopathy (208) 101
Angiotensin-converting enzyme (210) 77
Anterior spinal artery (207) 1
Antibodies (211) 67
α-1-Antichymotrypsin (210) 77
Anticoagulant therapy (212) 99
Anti-GAD autoantibody (208) 51
Anti-ganglioside antibodies (213) 11
Anti-ganglioside antibody (210) 99, (211) 89
Anti-GM1 antibody (210) 41
Anti-GM1b antibody (210) 41
Anti-GQ1b antibody (210) 105
Anti-GT1a antibody (210) 105
Anti-Hu associated paraneoplastic encephalomyelitis (213) 77
Anti-MAG antibodies (207) 43
Anti-MAG polyneuropathy (207) 43
Antiparkinsonian agents (212) 55
Antiplatelets (207) 5
Anxiolytic effect (211) 5
Apolipoprotein E (210) 77, (211) 15
Apolipoprotein E genotype (206) 31
Apomorphine (215) 105
Apoptosis (207) 51, (208) 17, (214) 27
Apparent diffusion coefficient (216) 11
Architecture (210) 47
Arterial occlusive diseases (207) 65
Artery (212) 79
Asclepius (213) 15
Ascorbate (215) 51
Assay (208) 1
Association study (209) 87, (213) 7
Astrocytes (208) 9
Asymptomatic stroke (214) 37
Ataxia (210) 53
Atheroscrelosis (207) 19
Atlastin (216) 43
Atopic dermatitis (206) 39
Atopic myelitis (206) 39
Atopy (206) 109, (209) 5
Atrophy (208) 57, (210) 5, (215) 45, (216) 169
Attention (213) 29
Attentional set-shifting (209) 19
Auditory midbrain (216) 143
Australia (213) 1
Autoimmunity (213) 55
Automated (216) 169
Autonomic nervous system (213) 47, (215) 79
Autonomic nervous system disorder (216) 17
Axon (206) 165
Axonal degeneration (210) 41
Axonal injury (206) 187
Axonal neuropathy (214) 3
Axonal transport blockage (211) 29
Axonal transport substances (211) 29

Baculovirus *p35* gene (216) 135
Baroreflex (213) 47
Basal ganglia (206) 27
αB-crystallin (206) 71
BDNF (215) 37
Best frequency (216) 143
Bickerstaff's brainstem encephalitis (211) 89
Bilateral frontal polymicrogyria (213) 83
Binding antibody (215) 3
Blood–brain barrier (215) 87
Blood donors (214) 49
Body fluids (208) 1
Body weight (206) 85
Bovine gangliosides (216) 99
Brain (210) 11, (210) 23
Brain death (210) 31
Brain edema (215) 87
Brain infarction (210) 95
Brain ischemia (212) 99
Brain parenchymal fraction (208) 57
Brainstem (208) 93, (208) 101

CAG repeat (215) 45
CAG repeats (216) 47
Calculation (208) 31
*Campylobacter jejuni* (210) 41, (210) 99, (213) 55
Cardiac autonomic modulation (216) 153

doi:10.1016/S0022-510X(03)00323-X

Cardiac [$^{123}$I]-MIBG-SPECT (216) 153
Cardioembolism (212) 99
Caregiver (209) 79
Carotid artery (207) 19, (210) 31, (213) 19
Carotid endarterectomy (213) 19
Cauda equina (208) 113
Caudate nucleus (216) 109
CCM (212) 75
CD29 (216) 61
CD4 count (208) 39
Central autonomic nervous system diseases (215) 79
Central conduction time (210) 83
Central core disease (206) 71
Central nervous system (213) 67
Cerebellar ataxia (208) 51, (216) 183
Cerebellum (208) 51, (213) 35
Cerebral (216) 169
Cerebral autoregulation (208) 71
Cerebral blood flow (208) 71, (213) 19
Cerebral edema (209) 69
Cerebral infarction (209) 69, (212) 79
Cerebral spinal fluid (CSF) (206) 145
Cerebral venous thrombosis (215) 9
Cerebrospinal fluid (207) 71, (208) 39, (211) 67, (212) 11
Cerebrotendinous xanthomatosis (216) 179
Cerebrovascular disorders history (213) 15
Cervical spondylosis (206) 39
Chaperonin 10 (212) 37, (216) 33
Charcot–Marie–Tooth disease (210) 61, (211) 93
Chemokine (208) 43
Chemokine receptor (216) 61
Chemoreflex (213) 47
Chenodeoxycholic acid (216) 179
Chinese (216) 55, (216) 81, (216) 163
Cholestanol (216) 179
Cholesterol (210) 11
Cholinesterase inhibitors (216) 119
Chorea (208) 109
Christus Medicus (213) 15
Chromosome 19 (213) 7
Chronic brain inflammation (212) 69
Chronic inflammatory demyelinating polyneuropathy (208) 39
Chronic inflammatory demyelinating polyneuropathy (CIDP) (208) 43, (210) 19
Circadian rhythm (212) 93
Circumscribed atrophy (209) 105
Citicoline (215) 105
Citrullinaemia (209) 101
Clinical characteristics (206) 131
Clinical Dementia Rating (215) 71
Clinical epidemiology (215) 63
Clinical–MRI correlation (206) 139
Clustering/random arrangement (211) 63
CMTX (207) 77
CNS inflammation (206) 49
Coagulation system (212) 55
Coffee (216) 163
Cognitive function (213) 19
Cognitive functions (211) 15
Cognitive impairment (216) 105
Color discrimination (213) 61
Color vision (213) 61
Combined treatment (216) 179
Complex III deficiency (208) 87
Complex partial status epilepticus (213) 77
Complication (209) 115
Computed tomography (CT) (208) 93
Conduction block (213) 11
Congenital hypomyelination (210) 61
Congenital myopathies (206) 71
Connexin 32 mutation (207) 77
Controlled trials (206) 123
Coordinated eye and head movements (213) 35
Copaxone® (215) 37
Cores (206) 71
Cortex (211) 85
Cortical excitability (215) 75
Cortical threshold (210) 83
Corticobasal degeneration (206) 97, (208) 31, (216) 127
Corticobasal degeneration syndrome (216) 127
Corticosteroids (208) 113
CSF (206) 43, (207) 87
CTG repeat (207) 31
CT scan (208) 25
Cultured neurons (206) 91
Cutaneous silent period (216) 67
Cu/Zn superoxide dismutase gene (206) 65
CXCR3 (216) 61
D-Cycloserine (210) 53
Cytoarchitecture (211) 75
Cytochrome *b* mutation (209) 61
Cytochrome *c* oxidase deficiency (211) 63
Cytochrome oxidase (212) 93
Cytokine (208) 43, (213) 11
Cytokines (215) 95, (216) 33
Cytomegalovirus (213) 55

Decreased saccadic latency (213) 35
Dejerine–Sottas syndrome (210) 61
Delayed-type hypersensitivity reaction (212) 37
Dementia (206) 23, (208) 87, (209) 105, (210) 77, (212) 79, (214) 37, (216) 119, (216) 169
Dementia with Lewy bodies (211) 29
Dementia with Lewy bodies (DLB) (216) 105
Demyelination (206) 187, (210) 19, (212) 37
Depression (209) 79, (211) 55
Developing country (209) 65
DGGE (210) 61
Diagnosis (210) 31
Diffuse brain disorders (213) 29
Diffuse neurofibrillary tangles with calcification (209) 105
Diffusion tensor (206) 157
Diffusion tensor MRI (206) 27
Diffusion-weighted imaging (210) 95, (212) 99
Diffusion-weighted MR (209) 101
Digit backward span (209) 19
Disability (206) 165, (206) 209, (209) 65
Disability evaluation (208) 57
Disease activity (211) 67
Disease progression (206) 123
Disuse (210) 5
L-DOPA sensitive Dystonia (213) 25
Dopamine (208) 9
Dopamine transporter gene (209) 87
Doppler (207) 65, (208) 71
Dose response (214) 43
Dural arteriovenous fistula (215) 115
Dynamics (212) 47
Dysconjugacy (210) 65
Dysferlin (211) 23
Dystonia (206) 59

EAE (206) 49
Early ischemic change (212) 99

Early pregnancy factor (212) 37, (214) 27, (216) 33
Education, Personality (211) 15
EEG (213) 83
Efficacy (211) 81
EGR2 (210) 61
Electromyography (214) 21
Electron transport chain (206) 23
Electrophysiological study (211) 89
Elevated plus-maze test (211) 5
ELISA (207) 43
Emery-Dreifuss (210) 47
Endothelin-1 (212) 59
Endplate (210) 5
Epidemiology (212) 31, (213) 1, (214) 7
Epidermal nerve fibers (214) 3
Epilepsy (209) 65, (213) 83
Epilepsy/EEG (211) 37
Epilepsy surgery (216) 153
Episodic ataxia type 2 (EA-2) (210) 91
Epitope mapping (206) 7
Epitope specificity (206) 7
Estrogen (210) 11
Etanercept (Enbrel®) (210) 19
Evan's blue (215) 87
Evoked potentials, Auditory (212) 1
Exercise intolerance (209) 61
Exonic deletion (207) 11
Experimental autoimmune encephalomyelitis (212) 37, (214) 27, (216) 33
Exteroceptive suppression (216) 67
Eye/head latencies (213) 35

Fabry's disease (214) 21
Falls (212) 47
Familial ALS (206) 65
Familial Alzheimer's disease (209) 75
FDG PET (212) 85
Femoral neuropathy (209) 119
[F-18]-FDG (210) 23
Fibrinolysis (212) 55
Filamin C (206) 71
First-pass amplitude (210) 65
Flexion myelopathy (206) 109
Flow cytometry (209) 93
Fluorodeoxyglucose (FDG) (215) 71
fMRI (213) 29
Folate (207) 19
Four-vessel occlusion (215) 87
Frequency (211) 23
Friedreich's ataxia (206) 59
Frontal cortex (209) 41
Frontal lobe function (214) 37
Frontotemporal dementia (206) 97, (208) 31
Functional magnetic resonance imaging (206) 157
Functional status (209) 65

GABA (208) 51
$GABA_A$ receptor (208) 51
$GABA_B$ receptor (208) 51
Gadolinium enhancement (213) 67
Gait (212) 47
Galectin-1 (208) 67
Gallium scan (208) 113
Ganglioside (213) 55
Gastric haemorrhage (208) 25
Gene analysis (210) 91
Gene dosage analysis (207) 11
Gene expression in Andeans (207) 37
Gene regulation (215) 95
Genetic polymorphism (209) 87
Genetics (213) 7
Genotype (210) 77
Giant cell arteritis (215) 27
Glatiramer acetate (215) 37
Glia (209) 31
Glioma (216) 1
Glutamate (206) 91
Glutamic acid decarboxylase (208) 51
Glutathione (207) 51, (215) 105
GM1 (210) 99
GQ1b (211) 89
Guillain–Barré syndrome (208) 39, (210) 99, (211) 93, (213) 11, (213) 55, (216) 99
Guillain-Barré syndrome (210) 41, (211) 89
Guillain–Barré syndrome (GBS) (215) 63

Habituation (212) 1
HAM/TSP (207) 87
Haploinsufficiency (210) 35
Haplotype (207) 11
Health-related quality of life (211) 55
Heart rate variability (216) 153
Heat shock protein (216) 33
*Helicobacter pylori* (213) 55
Hemiplegia (213) 15
Heparanase (206) 49
Heparin-mimicking polyanionic compound (HMPAC) (206) 49
Hepatic cirrhosis (212) 93
Hepatic encephalopathy (212) 93
Hereditary motor and sensory neuropathies (207) 77
Hereditary spastic paraplegia (216) 43
Heteroplasmy (211) 63
Hippocampus (209) 31
History of medicine, Medieval (213) 15
HIV (208) 39
HLA (211) 49
HMG-CoA reductase inhibitor (216) 179
1H-MRS (215) 21
HMSN (210) 61
$H_2O_2$ (216) 135
Homocysteinemia (207) 19
Hourglass-like fascicular constriction (215) 111
HTLV-I (206) 17, (207) 87, (214) 49
HTLV-I antibody index (207) 87
HTLV-I associated myelopathy (206) 17
HTLV-I-associated myelopathy (214) 49
HTLV-I-associated myelopathy/tropical spastic paraparesis (207) 87
Human chronic hypoxia (207) 37
Huntington's disease (212) 1
6-hydroxydopamine (215) 105
Hyperbaric oxygenation (209) 115
Hypertension (208) 93
Hypothermia (209) 55
Hypoxia (206) 187, (213) 47, (215) 57

ICAM-1 (211) 15
ICAM-1 meningitis (206) 43
Idiopathic intracranial hypertension (215) 9
IgE (209) 5
IL-8 (206) 43
IL-10 (206) 209
Iliacus muscle hematoma (209) 119
IL-23, IL-12, IL-23R, IL-12R (215) 95
Immunoblotting (211) 23
Immunocytochemistry (209) 31

Immunoglobulin G (206) 123
Immunoglobulins (206) 7
Immunohistochemistry (207) 43, (208) 67, (211) 23, (215) 119
Immunomodulation (206) 49
Immunosuppression (206) 203
Impedance cardiography (208) 71
Incidence (213) 1, (216) 89, (216) 99
Increased saccadic velocity (213) 35
Inflammatory demyelination (212) 21
Inflammatory myopathy (215) 119
Information processing (213) 29
Insert mutation (210) 35
In situ hybridisation (215) 27
Insula (212) 85
Interferon-β (207) 59
Interferon beta (206) 199, (216) 113
Interferon beta-1a (206) 215
Interferon beta 1a (215) 3
Interferon beta 1b (215) 3
Interferon-gamma (209) 93
Interleukin-6 (211) 15
International cooperative ataxia rating scale (210) 53
Internuclear ophthalmoparesis (210) 65
Intervertebral disc degeneration (206) 39
Intracerebral haemorrhage (208) 25
Intracranial hypertension (215) 9
Intracranial large artery disease (216) 55
Intracranial sinus venous thrombosis (215) 9
Intramedullary spinal cord lesion (216) 67
Intrathecal (211) 81
Intrathecal IgG synthesis (212) 69
Intravenous immunoglobulin (206) 123, (210) 105
Intravenous immunoglobulin (IVIg) therapy (208) 43
Intraventricular hemorrhage (215) 115
In vivo microdialysis (211) 5
Iopamidol transfer (206) 85
Isatin (206) 79
Ischemic cerebrovascular disease (206) 31
Ischemic stroke (207) 5
Isoelectric focusing (212) 69

Japanese (211) 49
Japanese encephalitis virus (206) 79
Japanese pedigree (209) 75

Korean family (206) 65
Kosaka–Shibayama disease (209) 105
*KRIT1* gene (212) 75

Laboratory markers (206) 131
Lactate (214) 17
Large vessel disease (214) 11
Lateral TLE (215) 21
Lazaroid (215) 87
LDL-apheresis (216) 179
LDL phenotype B (214) 11
LDL receptor (213) 7
Leukoencephalopathy (208) 93, (216) 183
Levodopa (212) 47, (216) 81
Lewy body (211) 29
Limb-girdle muscular dystrophy (LGMD) (211) 23
Local cooling (209) 55
Longitudinal study (216) 113
Long-term depression (LTD) (211) 43
Long-term potentiation (LTP) (211) 43
Low-grade glioma (214) 43
Lumbosacral radiculography (206) 85
Lymphocyte subsets (216) 61
Lymphocytes (214) 27
Lymphoid follicle (215) 119
Lymphomatoid granulomatosis (213) 67

Machado–Joseph disease (215) 45
Macrophage (208) 43
Macrophage colony-stimulating factor (M-CSF) (208) 43
Macrophages (214) 27
Madras motor neuron disease (209) 13
Madras motor neuron disease variant (209) 13
Magnesium (216) 95
Magnetic resonance imaging (206) 27, (206) 175, (206) 157, (208) 113, (211) 75, (212) 11, (213) 83, (214) 37, (215) 45, (216) 11
Magnetic resonance imaging (MRI) (206) 145, (208) 93, (210) 57
Magnetic resonance spectroscopy (207) 59
Magnetization transfer (206) 157
Mathematical model (216) 1
Matrix metalloproteinases (206) 43
Mechanical insufflation–exsufflation (209) 111
Mechanically assisted cough (209) 111
MELAS (216) 11
Membrane (216) 23
Mental calculation span (209) 19
Mesial (215) 21
Metabolism (216) 23
Methylenetetrahidrofolate reductase (MTHFR) (207) 19
Methylprednisolone (216) 61
Mice (208) 9
Microglia (215) 95
Middle cerebral artery (208) 71, (212) 59
Middle latency auditory-evoked potentials (207) 31
Migraine (213) 7, (216) 17
Mini-mental state examination (MMSE) (216) 105
Mite (209) 5
Mitochondria (206) 23, (207) 51, (208) 87
Mitochondrial DNA (211) 63
Mitochondrial encephalomyopathy (211) 63
Mitochondrial enzyme activity (214) 17
Mitochondrial myopathy (209) 61, (211) 63
Mitoxantrone (206) 203
Mixed connective tissue disease (215) 119
Miyoshi myopathy (MM) (211) 23
MMP-2 (207) 71
MMP-9 (207) 71
Molecular mimicry (210) 41
Monoamine oxidase inhibitor (206) 79
Monocyte chemoattractant protein-1 (MCP-1) (208) 43
Morphometry (210) 57
Motor amplitude (210) 83
Motor cortex (208) 79
Motor evoked potentials (216) 67
Motor neuron (206) 109, (208) 67
Motor neuron disease (209) 13, (214) 49, (216) 95
Motor neuron(s) (207) 51
Motor recovery (207) 25, (215) 13
Motor threshold (215) 75
Mouse (210) 11
Movement disorders (206) 59
MPTP (208) 9
MRI (206) 123, (206) 181, (206) 209, (208) 57, (209) 69, (210) 73, (211) 49, (211) 85, (212) 85, (213) 67, (215) 9, (216) 169
mRNA expression (216) 109
MR venography (215) 9
MS disease markers (212) 21
mtDNA mutation (214) 17
Multi-minicore disease (206) 71

Multiple sclerosis (206) 7, (206) 27, (206) 49, (206) 123, (206) 135, (206) 139, (206) 145, (206) 153, (206) 165, (206) 175, (206) 181, (206) 187, (206) 209, (208) 57, (209) 93, (210) 73, (211) 49, (211) 55, (211) 67, (212) 11, (213) 1, (214) 7, (214) 27, (215) 37, (215) 79, (216) 33, (216) 61, (216) 89, (216) 113, (216) 169
Multiple sclerosis drug therapy (206) 123
Multiple sclerosis (MS) (206) 193
Multiple system atrophy (211) 85
Multi-unit activity (212) 59
Muscle (208) 87
Muscle activation threshold (207) 25
Muscle atrophy (206) 109
Mutation (206) 65, (216) 43
Mutation analysis (211) 23
Myasthenia gravis (212) 31
Myelin-associated glycoprotein (MAG) (207) 43
Myelin basic protein (206) 7
Myelin oligodendrocyte glycoprotein (206) 7, (211) 67
Myelin proteins (206) 7
Myelin proteolipid protein (206) 7
Myelitis (209) 5
Myoclonus (209) 75
Myopathy (214) 49
Myotonic dystrophy (207) 31, (208) 87

NADPH-D (209) 31
L-NAME (215) 31
Nationwide survey (209) 5
Nerve conduction studies (214) 21
Nerve injury (211) 43
Nervous system (207) 37
Neuralgic amyotrophy (215) 111
Neural plasticity (216) 143
Neurodegeneration (207) 51, (207) 71
Neurodegenerative disorders (206) 23
Neurofibrillary tangles (208) 17
Neuroimaging (212) 85
Neuromuscular stimulation (207) 25
Neuronal antibodies (206) 131
Neuronal apoptosis (206) 91
Neuronal plasticity (208) 79
Neurons (209) 31
Neuropathy (206) 17
Neurophysiological study (210) 73
Neuroprotection (208) 9, (215) 31
Neuropsychological evaluation (209) 105
Neuropsychological test (213) 19
Neurosarcoidosis (208) 113, (211) 67
Neurotrauma (216) 23
Neutralizing antibody (215) 3
Nitrate (208) 1
Nitric oxide (208) 1
Nitrite (208) 1
NMDA (215) 31
NMDA receptor glycine site (210) 53
*N*-methyl-norsalsolinol (216) 109
NMR spectroscopy (212) 21
Nodular infiltrates (215) 119
Non-invasive positive pressure ventilation (209) 111
Non-invasive respiratory aids (209) 111
Normal brain aging (211) 15
Normal human cerebral cortex (211) 75
NOS isoforms (215) 31
Nosology (216) 127
NO synthase, $Ca^{2+}$ signaling (209) 47
Notch (212) 79
Nucleus (210) 47
Number (208) 31

6-OHDA (216) 135
$^{15}O-H_2O$ PET (212) 85
Oligodendrocytes (206) 181
ONO-2506 (208) 9
ONO-1714 (215) 31
Opioid receptor (216) 109
Optic atrophy (209) 13
Optic neuritis (211) 49
Orthostatic hypotension (208) 71
Osmotic agent (209) 69
Oxidative stress (216) 135
Oxygen–glucose deprivation (216) 23

$P_{300}$ (211) 15
Pain (212) 85
Painful neuropathy (215) 111
Painful sensory neuropathy (214) 3
Palliative care (209) 79
Paraneoplastic syndrome (213) 77
Parasympathetic nervous system (215) 79
PARK2 (207) 11
Parkinson (215) 105
Parkinson's disease (206) 79, (207) 11, (208) 9, (209) 19, (209) 41, (209) 87, (211) 85, (212) 47, (212) 55, (213) 61, (215) 51, (216) 81, (216) 163
Parkinson's disease (PD) (216) 105
Partial agonist (210) 53
PASAT (213) 29
Pathology (206) 17, (206) 165, (206) 175, (208) 101
Pattern recognition (212) 21
PC12 cell (216) 135
Peg insertion (213) 61
Percutaneous electric nerve stimulation (208) 79
Peripheral circulation (216) 17
Peripheral neuropathy (214) 49
Persistent vegetative state (212) 85
PET (210) 23
Phenotype (213) 25
Phosphene threshold (215) 75
Phosphorylated extracellular signal-regulated kinase (p-ERK) (215) 57
Phosphorylated serine/threonine kinase AKT (p-AKT) (215) 57
Photoplethysmography (216) 17
Pick's disease (206) 97, (216) 127
Plasma exchange (206) 109, (210) 105
Plethysmography (216) 17
$^{31}P$-Magnetic resonance spectroscopy (214) 17
Polymorphisms (210) 77
Polyneuropathy (210) 19, (213) 55
Pontine base (215) 45
Pontine tegmentum (215) 45
Poser diagnostic criteria (214) 7
Positron emission tomography (209) 105
Positron emission tomography (PET) (215) 71
Post-encephalitic parkinsonism (206) 79
Posterior inferior cerebellar artery (207) 1
Posterior interosseous nerve (215) 111
Posterior spondylolisthesis (206) 39
Post-hypoxic (210) 23
Pramipexole (216) 81
Predictive factors (212) 31
Prefrontal cortex (209) 41, (211) 5
Pregnancy (216) 33
Presbycusis (216) 143
Presenilin 1 (209) 75

Pretangle neurons (208) 17
Prevalence (213) 1, (214) 7, (216) 89
Prevalence rate (211) 49
Primary and secondary progressive (206) 153
Primary cultured neurons (215) 31
Primary progressive aphasia (206) 97
Primary progressive multiple sclerosis (206) 157, (206) 215
Prognostic indicator (215) 63
Progressive multiple sclerosis (206) 203, (211) 81
Progressive supranuclear palsy (211) 85
Progressive supranuclear palsy (PSP) (210) 57
Prospective study (215) 63
14-3-3 protein (212) 11
Pseudo-dominant inheritance (207) 11
Pseudotumor cerebri (215) 9
PTT (212) 75
Pulse sequence (216) 169
Purkinje cell (208) 51

Quality-of-life (209) 65
Quality of life (209) 79, (216) 113
Quantitative PCR (207) 87

Radial nerve palsy (215) 111
Radiation necrosis (209) 115
Radiosurgery (209) 115
Radiotherapy (214) 43
Rat (211) 5, (212) 59, (216) 109
Rat brain (209) 47
Reactive oxygen species (207) 51
Real-time PCR (210) 11
Recurrence (206) 31
Recurrent coma (209) 101
Regional cerebral blood flow (209) 25, (209) 41
Regucalcin (209) 47
Relapse (210) 105
Relapses (206) 123
Relapsing (206) 135
Relapsing–remitting (206) 153
Relapsing-remitting (216) 113
Relapsing–remitting multiple sclerosis (215) 3
Relaxation time (209) 69
Remitting (206) 135
Remyelination (206) 181, (206) 193
Reperfusion (215) 87, (216) 23
Repetitive transcranial magnetic stimulation (209) 41
Reproducibility (216) 169
Reproductive immunology (216) 33
Respiratory chain (206) 23
Resuscitation (210) 23
Reticular formation (212) 1
Retinol (215) 51
Retrosplenium of corpus callosum (210) 95
Revised version of Hasegawa's Dementia Scale (HDSR) (216) 105
Rivastigmine (206) 23, (216) 119
RNase protection assay (210) 11
Rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) (210) 57
Rostral midbrain (210) 57
Rural (209) 65

SCA 3 (213) 25
Scavenger receptors (210) 11
Secondary progression (206) 209
Secondary progressive MS (206) 131
Secondary progressive multiple sclerosis (206) 199
Sensorimotor deficit (212) 59
Sensory neuropathy (214) 3
Septicemia (208) 25
Serotonin (211) 5
Serotonin receptor (216) 109
Sexual dimorphism (209) 93
Sexual dysfunction (210) 73
SF-36 (211) 55
Side effects (216) 113
Single photon emission computed tomography (209) 25, (213) 19
Single unit responses (216) 143
Skin (208) 67
Small fibre neuropathy (208) 105, (214) 3
Small subcortical infarct (216) 55
Small vessel disease (214) 11
Smoking (216) 163
Somatosensory evoked potentials (216) 67
Sound exposure (216) 143
South Africa (216) 47
Spain (216) 89
Spastic paraplegia (210) 35
Spastin (210) 35
SPECT (209) 41, (216) 119
Spectral analysis (208) 71
SPG4 (210) 35
SPG3A (216) 43
Spheroid (208) 67
Sphincteric dysfunction (210) 73
Spinal cord (214) 27
Spinal cord infiltrating cells (212) 37
Spinal nerve root sleeves (206) 85
Spinocerebellar ataxia, or inherited ataxias (216) 47
Spinocerebellar atrophy (213) 25
Spinocerebellar degeneration (210) 53
Statins (208) 105
Status epilepticus (211) 37
St. Bonaventure (213) 15
St. Francis (213) 15
Stroke (207) 25, (210) 77, (215) 13
Stroke classification (207) 65
Stroke-like episodes (214) 17
Stroke model (212) 59
Subacute sclerosing panencephalitis (207) 59
Subependymal vein (215) 115
Subgroup (215) 63
Sudden coma (212) 99
Sudden unexplained death in epilepsy (216) 153
Superoxide dismutase (216) 95
Superoxide dismutase 1 (SOD1) (206) 65, (215) 57
Suprachiasmatic nucleus (212) 93
Supranuclear gaze palsy (210) 57
Survey (211) 37
Sympathetic nervous system (215) 79
Sympathetic skin response (208) 105, (214) 21
Synapse (210) 5
α-Synuclein (211) 29
Systemic cooling (209) 55
Systemic hypotension (207) 1

Taiwanese (209) 87
Target formations (206) 71
T1 black holes (208) 57
Tea (216) 163
Temperature (209) 55
Temporal artery (215) 27
Temporal lobe epilepsy (215) 21
Temporal pattern (216) 99
Th1 (216) 61

The central nervous system involvement (207) 31
The *parkin* gene (207) 11
Therapeutics (206) 215
Therapy (210) 19, (216) 95
Thermal hyperalgesia (211) 43
Thrombomodulin (212) 55
Thymectomy (212) 31
Thymus (212) 31
TIA (207) 5
TIMP-1 (207) 71
TIMP-2 (207) 71
T2 lesions (208) 57
Tocopherol (215) 51
tonic–clonic seizure (209) 75
Trail Making Test (209) 19
Transcranial (207) 65
Transcranial Doppler (210) 31
Transcranial magnetic stimulation (210) 83, (211) 5, (213) 35, (215) 75
Transcutaneous electrical nerve stimulation (TENS) (211) 43
Transection (206) 165
Transgenic mouse (216) 95
Transient global amnesia (210) 95
Transvenous embolization (215) 115
Transverse–sigmoid sinuses (215) 115
Traumatic spinal cord injury (209) 55
Treatment (206) 79
Treatment choices (209) 79
Treatment trials (206) 139
Triamcinolone acetonide (211) 81
Tropical spastic paraparesis (206) 17
Tuberculoma (208) 109
Tuberculous meningitis (208) 109
Tumor growth (216) 1
Tumor invasion (216) 1
Tumor necrosis factor-alpha (209) 93
Tumor necrosis factor (TNF) (210) 19
TUNEL (208) 17
Turner's syndrome (213) 83
Tyrosine hydroxylase (215) 105

U-74389G (215) 87
Ultrasonography (207) 19, (207) 65
Ultrasound (210) 31
Unweighting (210) 5
Urine (212) 21
Urodynamic study (210) 73

Vanadium (208) 1
Variable number tandem repeat polymorphism (209) 87
Varicella-Zoster virus (VZV) (215) 27
Vascular (212) 79
Vascular damage (206) 187
Vascular parkinsonism (215) 51
Vasculitis (208) 101
Veins (208) 101
Vertebral artery stenosis (207) 1
Video-assisted thoracoscopic extended thymectomy (VATET) (212) 31
Viliuisk encephalomyelitis (212) 69
Viral load (207) 87
Visual evoked potential (VEP) (206) 193
Visual loss (216) 11
Vitamin A (215) 51
Vitamin $B_{12}$ deficiency (216) 183
Vitamin C (215) 51
Vitamin E (215) 51

Western blot (212) 11
Western blot analysis (207) 43
Working memory (208) 31, (209) 19

X-linked Charcot–Marie–Tooth (207) 77

Zoster myelopathy (212) 7
Zoster paresis (212) 7
Zoster sine herpete (212) 7
*Z*-score (210) 65